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Abstract 
Background 
Anderson – Fabry Disease (AFD) is an X-linked lysosomal storage disorder that results 
in a deficiency in lysosomal -galactosidase A.  This leads to an accumulation of 
glycosphingolipids in multiple cell types resulting in the characteristic angiokeratomata, 
acroparesthesiae, hypohidrosis, and corneal opacities of classical AFD.  Although 
patients with AFD have a reduced life span, the pathogenesis and impact of cardiac 
involvement on prognosis remain unclear.  The aim of this thesis was to clinically 
characterise cardiac involvement in AFD using a systematic cardiac assessment of a 
consecutive cohort of patients with AFD. 
 
Methods  
A cardiac assessment protocol including history and examination, 12 lead ECG, 24 hour 
ambulatory ECG monitoring, echocardiography and cardiopulmonary exercise testing 
were performed in a cohort of 122 consecutive patients.  Subgroups had coronary flow 
reserve and evaluation of serum levels of MMP-9, TIMP-1 and TIMP-2 to assess 
coronary microvascular function and extracellular matrix (ECM) turnover, respectively.   
 
Results 
The main results of the thesis are as follows: (1) Tachy and brady arrhythmias are 
common and may contribute to premature death;  (2) Left ventricular systolic 
impairment is common and decline in systolic function may represent a measure of 
disease severity;  (3)  objective evidence for exercise limitation is common and is 
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related to overall disease severity as assessed with a validated disease severity score;  
(4) patients with AFD have markedly abnormal coronary microvascular function which 
does not improve with ERT; (5) patients with AFD have abnormal ECM turnover 
associated with overall disease severity.   
 
Conclusion 
Patients with AFD related cardiomyopathy have progressive disease characterised by 
heart failure and arrhythmia. It is likely that myocardial ischaemia and abnormal 
interstitial turnover are related in the pathogenesis of cardiac disease and 
complications.  Patients with AFD need regular and continued cardiac follow up for 
early identification and treatment of cardiac complications.  
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Preface 
Anderson – Fabry Disease (AFD) is an X-linked lysosomal storage disorder that results 
in a deficiency in the activity of lysosomal -galactosidase A, leading to an accumulation 
of glycosphingolipids in multiple different cell types.  This in turn causes the 
characteristic angiokeratomata, acroparesthesiae, hypohidrosis, and corneal opacities 
of classical AFD.  AFD related heart disease is common, but its impact on prognosis 
remains unclear. 
 
When I started my work in AFD, the evidence for cardiac involvement in AFD was in the 
form of case reports and case series.  There had been few systematic studies to look at 
the prevalence of left ventricular failure, arrhythmia and exercise limitation in patients 
with AFD.  Our collaboration with The Lysosmal Disorders Unit, The Charles Dent 
Metabolic unit and our own tertiary referral population of patients with unexplained 
left ventricular hypertrophy provided a unique opportunity to characterise cardiac 
involvement in AFD.  This thesis is a systematic and comprehensive clinical cardiac 
evaluation of patients with AFD.  The data presented are contemporary with my period 
as a research fellow.  Since completion of my work numerous studies on AFD related 
heart disease have been published.  I put my own work into the context of these data 
in the discussion.     
 
  
6 
 
Acknowledgements 
The work in this thesis was undertaken during my period as a clinical research fellow at 
The Heart Hospital, University College London Hospital. The following have greatly 
assisted in its completion: 
 
Professor Perry M Elliott: He introduced me to the field of hypertrophic 
cardiomyopathy. His support and supervision in the planning, development and writing 
of this thesis and manuscripts related to the research has been invaluable.  His 
unstoppable drive, passion and vision have been an inspiration. He was not only a 
supervisor and mentor, but also a friend.  I am honoured to have had the opportunity 
to have worked with him. 
 
Professor William McKenna: for his supervision and constructive criticisms of the 
project. 
 
The Research Team at The Heart Hospital:  for their continued support throughout my 
time as a research fellow. They all have been invaluable sources of wisdom and have 
provided a steadying influence through all the phases of this project. 
 
The staff of The Lysosomal Disease Unit, The Royal Free Hospital and The Charles Dent 
Metabolic Unit, The National Hospital for Neurology and Neurosurgery: For their 
continued support throughout my time as a research fellow and beyond.   
 
7 
 
Colleagues at City Hospital, Birmingham: For their expertise in the extra cellular 
matrix. 
 
Colleagues at MRC Clinical Sciences Centre, Imperial College, London: For their 
expertise in coronary flow reserve 
 
TKT-5S (Now Shire Human Genetic Therapies) and Sheila Bone: For funding my 
research and providing me with the opportunities that have resulted in this work. 
 
My wife and family: For their support and forgiveness for ‘bringing work home’. 
 
  
8 
 
Table of contents 
Abstract p3 
Preface p5 
Acknowledgement p6 
Contents p8 
List of figures p9 
List of table’s p11 
List of abbreviations p12 
1: Introduction        p14  
2: Characterisation of cardiac arrhythmia    p38 
3: The natural history of left ventricular systolic performance p57 
4: Exercise capacity       p69 
5: Coronary microvascular function, its relationship to                   p85 
symptoms and response to enzyme replacement therapy   
6: Extracellular matrix turnover in Anderson-Fabry disease                 p100 
7: Summary of findings and current literature    p115 
8: References        p129 
9: Publications arising from dissertation     p158
    
 
  
9 
 
List of figures 
Figure 1.1: Disease course in classical AFD     p17 
 
Figure 1.2: Johannes Fabry and William Anderson    p18 
 
Figure 1.3: Angiokeratomata       p27 
 
Figure 1.4:  Cornea Verticillata       p28 
 
Figure 1.5: Anderson Fabry disease cardiomyopathy histology   p30 
 
Figure 1.6: Fibrosis in Anderson Fabry disease cardiomyopathy p31 
 
Figure 2.1: Complete heart block p47 
 
Figure 2.2a:  Age adjusted prevalence of arrhythmia in Anderson-Fabry p50  
Disease in Males 
 
Figure 2.2b:  Age adjusted prevalence of arrhythmia in Anderson-Fabry p51  
Disease in Females 
 
Figure 2.3: Non-Sustained Ventricular Tachycardia p53 
10 
 
Figure 3.1:  The Change in Left Ventricular End Systolic Diameter  p65 
and Left Ventricular End Diastolic Diameter During Follow Up 
 
Figure 3.2:  The Change in Fractional Shortening During Follow Up p66 
 
Figure 4.1: Correlation between percentage predicted VO2 max and MSSI p81  
Score 
 
Figure 5.1: Myocardial Blood Flow at Rest and During Adenosine-Induced p95  
Hyperaemia in Patients with Anderson-Fabry Disease and Controls 
 
Figure 5.2: Myocardial Blood Flow at Rest and During Adenosine-Induced p96 
Hyperaemia Pre- and Post-Enzyme Replacement Therapy (FabrazymeTM) 
 
Figure 6.1: Difference in Matrix Metalloproteinase–9 between Patients and p108 
Controls 
 
Figure 6.2: Correlation between Metalloproteinase–9 and Disease Severity p109 
 
Figure 6.3: Correlation between Metalloproteinase–9 and Fractional p110  
Shortening 
 
  
11 
 
List of tables 
Table 1.1: Studies of prevalence of AFD p21 
 
Table 1.2 Signs and symptoms of Fabry Disease p23  
 
Table 2.1: Symptoms at Baseline Evaluation in Males and Females p46  
 
Table 2.2: Baseline Evaluation Indices in Males and Females p49  
 
Table 3.1: Anderson-Fabry Disease Symptoms and Baseline p63 
Echocardiographic Findings 
 
Table 4.1: Mainz Severity Score Index p73  
 
Table 4.2: Anderson - Fabry Disease Symptoms and Signs Stratified by Gender p77  
 
Table 4.3: ECG and Echocardiographic Data Stratified by Gender p79  
 
Table 4.4: Exercise Data Stratified by Gender p80  
 
Table 5.1: Patient characteristics p93  
 
Table 6.1: Baseline Characteristics in Males and Females p106 
12 
 
List of abbreviations 
AFD  Anderson Fabry Disease 
ECG  Electrocardiogram 
MMP  Matrix metalloproteinase 
TIMP  Tissue inhibitors of metalloproteinase 
ECM  Extracellular matrix turnover 
LSD  Lysosomal storage disorders 
Gb3  Globotriaosylceramide 
A-Gal  α – galactosidase A 
FOS  Fabry outcome survey 
AF  Atrial fibrillation 
PAF  Paroxysmal atrial fibrillation 
NSVT  Non-sustained ventricular tachycardia 
NYHA  New York Heart Association 
ERT  Enzyme replacement therapy 
RE  Romhilt-Estes score 
LVed  End diastolic left ventricular internal cavity diameter 
LVes  End systolic left ventricular internal cavity diameter 
IVS  Interventricular septum 
PW  Posterior wall 
RWT  Relative wall thickness 
FS  Fractional shortening 
LV  Left ventricular 
LVH  Left ventricular hypertrophy 
13 
 
HCM  Hypertrophic cardiomyopathy 
CPET  Cardiopulmonary exercise testing 
pVO2  Oxygen consumption at peak exercise 
%VO2max Per cent of predicted oxygen consumption at peak exercise 
MSSI  Mainz severity score index 
VCO2  Carbon dioxide output 
RQ  Respiratory quotient 
AT  Anaerobic threshold  
O2P  Oxygen pulse 
SV  Stroke volume 
A-V  systemic arteriovenous oxygen difference 
CFR  Coronary flow reserve 
MBF  Myocardial blood flow 
PET  Positron emission tomography 
ARSAC  Administration of radioactive substances advisory committee  
RPP  Rate pressure product 
  
14 
 
 
 
Chapter 1 
 
Introduction 
  
15 
 
Introduction 
Lysosomal storage disorders (LSD) are a distinct group of diseases that are the result of 
genetic defects in the genes encoding lysosomal enzymes or structural proteins1.  
Absent or reduced enzyme levels result in the accumulation of lysosomal storage 
products that would normally be degraded by the affected enzyme.  The diseases are 
categorised according to the type of storage product that accumulates (e.g. 
mucopolysaccharidoses and glycoproteinoses2).  
 
LSD are characterised by a progressive disease course and premature death.  They are 
individually rare with population incidences ranging from 1 in 57 000 live births for 
Gaucher’s disease and 1 in 4.2 million live births for Sialidosis3; however as a group their 
incidence has been estimated as 1 in 7000-8000 live births3, 4.  
 
The lysosome 
In the late 1950s and 60s, Christian De Duve, using cell fractionation techniques, 
cytological studies and biochemical analysis, characterised the lysosome as the 
intracellular organelle responsible for the degradation and recycling of 
macromolecules5-7.  This scientific breakthrough led to the physiological understanding 
of LSDs, with Pompe’s disease being the first to be identified in 1963 by Hers and 
colleagues8, 9.  Much subsequent research has focused on diagnosis (both prenatal and 
postnatal), carrier identification and the development of specific therapies. 
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Anderson – Fabry disease 
AFD is an X-linked lysosomal storage disorder resulting in systemic accumulation of 
lysosomal globotriaosylceramide (Gb3) due to a deficiency in lysosomal α-galactosidase 
A (A-Gal) activity1.  AFD is unlike most other X-linked conditions as it can affect both 
genders although the course of the disease in females may be delayed in presentation1.  
The disease is characterised by progressive clinical manifestation of multiple organ 
system involvement, with symptoms usually presenting in childhood, and premature 
death from stroke, renal or cardiac involvement10 (Figure 1.1). 
 
The history of Anderson-Fabry disease 
The first descriptions of AFD were made simultaneously by two independently working 
physicians in 1898.  William Anderson and Johannes Fabry described ‘angiokeratoma 
corporis diffusum’, the characteristic cutaneous manifestation of AFD (Figure 1.2) 11, 12.   
 
William Anderson, who trained at St Thomas’s Hospital, saw his first patient with the 
rash, without commenting on the underlying cause.  Johannes Fabry was a 
dermatologist at the University of Bonn.  He described a 13 year old boy who had 
previously developed an eruption starting at the back of his left knee and spreading to 
his thigh.  He thought that the disease may be a form of naevus or represent a 
developmental defect.  Both these physicians saw their patients in 1897 and in 
recognition of this the disease is sometimes referred to as Anderson – Fabry disease.  
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Figure 1.1: Disease course in classical AFD 
 
 
Figure 1.1 legend: adapted from Linhart et al13 
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Figure 1.2: Johannes Fabry and William Anderson   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 legend: Johannes Fabry and William Anderson respectively  
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Between 1909 and 1939 many physicians described the multi-organ involvement in 
AFD with a suspicion that there was a common cause behind all the symptoms14-16.  In 
1947, an autopsy demonstrated changes in the entire vascular system with 
accumulation of a peptide like substance17.  These findings were confirmed in another 
autopsy in 1950 where birefringent Maltese-cross-like structures under polarized light 
were noted as a typical pathological feature and characterised as phosphoglycolipid18.  
It was until the late 50s that it was felt that AFD only affected males but in 1959 Colley 
reported possible involvement in females19.  This was contrary to prevalent literature 
at the time20.  In 1964 de Groot published on a single family of 45 individuals spanning 
4 generations (including females with minimal symptoms) and characterised AFD as a 
dominant hereditary disturbance of lipid metabolism.  He commented on the 
discrepancy between severity of symptoms in females as opposed to males was 
incongruous with it being a dominant hereditary disturbance21. 
 
With the use of an electron microscope, Hashimoto et al identified the lysosome in a 
patient with AFD and commented on the lysosomes being ‘extremely overcrowded’22.  
In this study he concluded that the cause of AFD was a genetic disturbance in a 
lysosomal enzyme.  In the same year it was realised that AFD was a sex linked genetic 
enzyme deficiency.  It was noted that there was occasional penetrance in heterozygous 
females and constant penetrance in hemizygous males23.  Additionally in the same year 
the genetic deficit was isolated to the long arm of the X chromosome (locus Xg)24. 
 
In 1967 the enzyme deficiency of ceramidetrihexosidase and subsequent substrate 
accumulation was identified as the underlying cause of AFD25.  In 1972, it was reported 
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that AFD was corrected with kidney transplantation26, subsequently the treatment of a 
patient with purified ceramidetrihexosidase was described in 197327. 
 
The epidemiology of AFD 
Reported prevalence of AFD ranges from 1 in 476,000 to 1 in 117,000 in the general 
population3, 4, based on the total number of cases identified in a particular period 
divided by the total number of births in that same period. These figures have important 
limitations due to the nature of the studies, the failure to detect asymptomatic carriers 
(particularly women) and misdiagnosed cases resulting in significantly under estimated 
figures. Table 1.1 demonstrates that systematic new born screening reveals a higher 
incidence than thought previously.  The consistently high incidence of AFD in these 
systematic new born screening studies suggests that AFD is pan ethnic28-32 and suggest 
that the cardiac predominant genotypes may be more common than previously 
estimated29, 33.   
 
The tests used in these studies, for new born screening (flourometry, flow-injection 
tandem mass spectrometry or digital micro fluidics) have a positive predictive value 
ranging from 3.8 to 54% with appreciable false positive rates34.  There is a lack of 
prospective new born screening and treatment studies in AFD and uncertainty 
regarding effectiveness of and immunologic response to treatment make this kind of 
screening controversial.      
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Table 1.1: Studies of prevalence of AFD 
Type of study Study period Number per 100,000 Country 
Birth prevalence 1980-1996 0.85 Austrailia3 
Birth prevalence 1970-1996 0.21 Netherlands4 
Prevalence of obligate carriers (females) 1980-1995 0.29 UK35 
Prevalence 1980-1995 0.27 UK10 
Birth prevalence 1997-2002 0.015 Turkey30 
Birth prevalence 1982-2001 0.12 Portugal31 
Neonatal screening 2004-2006 30 Italy32 
Neonatal screening 2006-2008 80 Taiwan33 
Neonatal screening 2007-2010 14 Japan28 
Neonatal screening 2013 (6 months) 34 Missouri29 
 
Table 1.1 legend: Table adapted from Germain36 
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Molecular genetics of AFD 
AFD results from mutations in the galactosidase gene (GLA), located on the long arm 
of the X-chromosome (Xq22.1) which encodes a 101 kDa homodimeric glycoprotein 
that exists in a number of natural forms resulting from variations in sialic acid residues 
on carbohydrate chains1.  Over 600 mutations have been described in all seven gene 
exons, the majority (57%) being mis-sense point mutations with some premature stop 
codons, splice site mutations and insertion/deletions1, 37-42.  Reduced enzyme activity 
occurs by several mechanisms including abnormal/unstable protein folding, 
perturbation to active binding site, and defects in enzyme tracking to the lysosome1, 40.  
Despite this condition being described as an X-linked recessive disease, female carriers 
also develop symptoms and signs of the disease.  This is thought to be related to the 
mechanism of non-random X chromosome inactivation (Lyonisation)43 
 
Clinical presentation 
Patients with AFD can present with non-specific symptoms, resulting in a delay in 
diagnosis. Data from the Fabry Outcome Survey (FOS), an International prospective 
registry study, suggest that there is a delay of 13.7 years for males and 16.3 years for 
females from the onset of symptoms to diagnosis44.  Overall, 25% of patients in FOS 
have reported a previous misdiagnosis44. 
 
In the FOS study the most frequently reported signs and symptoms were neurological44. 
Both male and female patients had a high prevalence of neuropathic pain (76% and 
64%, respectively) occurring with earlier age of onset in males than in females. 
Angiokeratomata occurred in 78% of males and 50% of females.  
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Table 1.2 Signs and symptoms of AFD 
Organ system Sign/symptom 
Nervous system 
Acroparesthesiae 
Tinnitus/hearing loss 
Heat intolerance 
Stroke 
  
Gastrointestinal tract 
Nausea, vomiting, bloating, diarrhoea (irritable bowel syndrome like symptoms) 
Difficulty gaining weight 
  
Skin 
Angiokeratomata 
Hypo/anhidrosis 
  
Eyes Corneal and lenticular opacities (‘cornea verticillata’) 
  
Kidney 
Microalbuminuria/proteinuria 
Hyperfiltration 
Renal failure requiring dialysis 
  
Heart 
Arrhythmia 
Left ventricular hypertrophy 
Heart failure 
Angina, breathlessness, palpitation, syncope, sudden death 
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Fifty percent of patients with AFD had signs and symptoms of renal disease, the 
commonest being proteinuria observed in 44% of males and 33% of females. End-stage 
renal failure was present in 17% of males and 1% of females. Women (27%) had a 
higher prevalence of cerebrovascular events than men (17%), with the events occurring 
at a younger age in males than in females. Auditory symptoms, such as tinnitus and 
hearing loss, were present in more than 50% of patients and ocular signs in just less 
than 60% at presentation. Gastrointestinal symptoms, including abdominal pain and 
diarrhoea were present in approximately 50% of patients with AFD. Fatigue was 
reported as a major symptom in approximately 20% of patients44.  Table 1.2 describes 
the signs and symptoms of AFD stratified by organ system. 
 
Neurology 
Early neural damage affects the small nerve fibres of the peripheral somatic and 
autonomic nerve systems resulting in the characteristic acroparasthesiae, hypohidrosis 
and gastrointestinal symptoms45, 46.  Patients describe two types of pain: 
(a) ‘Fabry crisis’ – these are episodic crises of agonizing burning pains in the 
extremities radiating inward to the limbs and other parts of the body. These crises 
may be precipitated by fever, fatigue, exercise and rapid changes in temperature47. 
Crises are often accompanied with a raised erythrocyte sedimentation rate, resulting 
in misdiagnosis such as rheumatoid arthritis and Raynaud’s phenomenon; (b) Chronic 
pain characterised by chronic burning and tingling paraesthesia46.  Both types of pain 
often wane in adulthood and so it is important to question patients about childhood 
symptoms. 
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Cerebrovascular involvement in AFD can lead to a variety of symptoms and signs 
including headache, vertigo/dizziness, transient ischaemic attacks, ischaemic strokes 
and rarely vascular dementia48, 49.  The potential pathophysiology behind 
cerebrovascular disease in AFD includes multifocal involvement of small vessels, 
increased thrombotic potential (measurable activation of the endothelium and 
leukocytes), dilative arteriopathy in the vertibrobasilar circulation and changes in 
regional cerebral hyperperfusion50-52.  In one large study of patients with AFD, the 
prevalence of cryptogenic stroke was 6.9% in males and 4.3% in females with the 
median age at presentation of 39 in males and 46 in females53.  
Auditory and vestibular involvement results in a range of symptoms from hearing loss 
(progressive or sudden), tinnitus and vertigo44.  The mechanism of these symptoms is 
likely to be related to both neuropathy and vasculopathy. 
 
Gastrointestinal 
The gastrointestinal symptoms are under-appreciated, they include post prandial 
abdominal pain, diarrhoea, vomiting and failure to gain weight45.  These symptoms are 
caused by deposition of Gb3 in the autonomic ganglia of the bowel and mesenteric 
blood vessels54. 
 
Skin 
The most visible clinical feature of AFD is angiokeratomata consisting of clusters of 
small reddish purple, and raised skin lesions (Figure 1.3).  These are typically found on 
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the buttocks, groin, umbilicus and upper thighs and sometimes on mucous 
membranes10, 55, 56.  Histologically, the skin lesions are small superficial angiomas 
caused by cumulative damage of the vascular endothelial cells of the skin with vessel 
dilatation in the dermis that increase in number and size with age and can occur singly 
or in groups55, 56.  Anhidrosis and hypohidrosis are attributable to selective peripheral 
nerve damage or to intracytoplasmic lipid deposits in the sweat glands57.  This results 
in exercise and heat intolerance46. 
 
Eye changes 
Patients frequently have corneal changes (‘cornea verticillata’), these are readily 
detectable on slit lamp examination, but do not have any impact on visual acuity (Figure 
1.4)58.  There are also descriptions of increased retinal vascular tortuosity58. 
 
Renal involvement 
Renal involvement is a major cause of morbidity and mortality in AFD44.  Like several 
aspects of AFD, renal involvement is progressive and increases in severity with age 
(Figure 1.1)13.  Renal impairment is thought to be a direct consequence of GB3 
deposition in glomerular endothelial, mesangial, interstitial cells and podocytes59.  
Initially patients develop microalbuminuria and proteinuria in the 2nd and 3rd decades 
of life60.  
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Figure 1.3: Angiokeratoma 
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Figure 1.4:  Cornea Verticillata 
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Progressive disease results in worsening proteinuria and a reduction in glomerular 
filtration, generally in the 3rd to 5th decade of life60.  At this stage fibrosis, sclerosis and 
tubular atrophy predominate on histology with end stage renal disease occurring in 4th-
5th decade of life59, 60. 
 
Cardiac disease in AFD 
Cardiac involvement in AFD begins early (Figure 1.1), with the average age for clinically 
overt symptoms being 32 years in the male and 40 years in the female 44.  Cardiac 
disease in AFD, as with other organ systems is associated with progressive Gb3 
accumulation in all cellular components of the heart.  Histological studies have 
identified GB3 in cardiomyocytes, conduction system cells, valvular fibroblasts, 
endothelial cells and vascular smooth muscle cells 61, 62.   
 
Cardiomyocytes are vacuolated and hypertrophied, but unlike familial hypertrophic 
cardiomyopathy, myofibrillar disarray is not prominent 62.  Lysosomal inclusions are 
present within myofibrils and vascular structures; fibrosis is evident within the mid-
myocardial layers and the posterolateral segments of the left ventricle (Figures 1.5 and 
1.6) 63.  While Gb3 accumulation is the most prominent feature histologically, it 
represents only 1–2% of the total cardiac mass64.  Therefore, it is likely that disease in 
the heart results from activation of other signalling pathways that lead to hypertrophy, 
apoptosis, necrosis and fibrosis.  These progressive changes correlate with 
observations of relatively mild diastolic dysfunction in early stages of the disease 
progressing to systolic and severe diastolic ventricular impairment in advanced 
disease64.  
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Figure 1.5: AFD cardiomyopathy histology 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 Legend: Haematoxylin and eosin stain (x100) demonstrating myocyte hypertrophy and vacuolization from GB3 accumulation within the cell.
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Figure 1.6: Fibrosis in Fabry disease cardiomyopathy 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 legend: Localised myocardial scar seen on cardiac MRI scan correlated to myocardial fibrosis on Picro-sirius red staining at post mortem examination of the 
same heart, in the absence of significant coronary artery disease 
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The ‘cardiac variant’ 
Patients with residual enzyme activity (1-5%) can have a delayed presentation in middle 
age with predominantly cardiovascular symptoms, LVH, cardiac rhythm abnormalities 
and valve disease65-67. However, while there is an absence of other ‘classical features’, 
rigorous clinical characterisation usually reveals organ involvement elsewhere. Hence 
AFD should be considered in all patients with otherwise unexplained left ventricular 
hypertrophy from the middle decade of life. 
 
Heart disease in females 
Clinical manifestations have generally been thought to be rare or mild in female 
carriers.  However, data from the Fabry Outcome Survey (FOS) and other sources show 
that most patients have signs or symptoms of disease with a similar prevalence of 
fatigue, neurological, gastrointestinal signs and symptoms in men and women10, 35, 44. 
Despite a lower prevalence of left ventricular hypertrophy, females have a similar 
prevalence of cardiac symptoms such as angina, dyspnoea and palpitations44. The 
prevalence of AFD related symptoms and signs increase with age in both males and 
females and it is suggested that females with AFD have a 15 year reduction in their life 
span when compared to the general population35. A study by Kampmann et al which 
examined 55 females with AFD confirmed on mutational analysis showed that the 
severity of the cardiac involvement in this group of patients may be as great as in that 
of males68.  A twin study has suggested the mechanism of non-random X inactivation 
(Lyonisation) may result in disease expression in females43. This hypothesis is further 
strengthened by a recent study that demonstrates a higher Mainz Severity Score (a 
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validated severity score for disease severity) in females with non-random X inactivation 
demonstrated in peripheral blood compared to those without69. 
 
Enzyme replacement therapy 
Exogenous proteins result in the possibility of sensitising the patient with a resulting 
reduced efficacy or allergy to the protein, hence initial efforts at enzyme replacement 
therapy (ERT) focused on a human source of A-Gal.  Enzyme extracted from human 
placental tissue was infused into 2 patients with AFD it resulted in a rapid reduction in 
circulating Gb3, returning to pre-infusion levels in 48 hours27.  Additional studies were 
carried out with A-Gal extracted from spleen and plasma with promising results70; 
however it became apparent that these sources would only provide limited quantities 
of the enzyme.  This resulted in 2 biotechnology corporations synthesising recombinant 
A-Gal.  Transkaryotic Therapies, Inc., Cambridge MA, subsequently known as Shire 
Human Genetic Therapies, Inc. A-Gal was initially produced in a cultured human skin 
fibroblast cell line using a proprietary gene-activation technique.  Known as 
Agalsidase–alfa (ReplagalTM) it is administered in a dose of 0.2 mg/kg of body weight 
every second week in intravenous (iv) infusions of 40 min.  Initial studies with this 
infusion resulted in > 30% reduction in hepatic and urinary Gb371. A randomised 
controlled trial by Schiffmann et al demonstrated a significant improvement in 
neuropathic pain, renal function, cardiac conduction and weight gain72.  
 
34 
 
The Genzyme Corporation, Cambridge, MA, used transduced Chinese hamster ovary 
cells to produce recombinant a-galactosidase A, Agalsidase–beta (FabrazymeTM), also 
administered on a biweekly basis, but in a dose of 1 mg/kg in a 4–6 h iv infusion.  The 
initial trial with agalsidase beta revealed clearance of Gb3 from the kidney, skin and 
heart and reduction of plasma and urinary Gb3 levels73.  This study demonstrated that 
88% of patients developed antibodies to the enzyme, but it was felt that this did not 
affect the efficacy end points73.    
 
Several studies using both enzyme products have demonstrated an improvement in 
renal, neurological and quality of life improvements72, 73.  There has been a phase three 
trial that has demonstrated a reduction in QRS duration on ECG, cardiac structural and 
functional improvement and clearance of GB3 from the vascular endothelium72, 74, 75.  
However, post mortem studies have demonstrated continued GB3 storage within 
myocytes despite several years of enzyme replacement therapy76.  The true prognostic 
effect of enzyme replacement therapy remains to be determined.  
 
Aims of the thesis 
Exercise limitation 
Male and female patients with AFD have an equal prevalence of cardiac symptoms, 
including effort intolerance, despite differences in the severity of cardiac disease at 
presentation68, 77, 78.  The mechanism and clinical significance of exercise limitation in 
patients with AFD have not been studied in detail.  I will determine the exercise capacity 
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in a large referral population of patients with AFD and its relation to markers of disease 
severity. 
 
Left ventricular function 
I have described above that there are data to support progressive left ventricular 
hypertrophy.  Weidemann et al. demonstrate that enzyme replacement therapy 
improves cardiac contractile function as measured by strain rate on echocardiography, 
however there are no data to document the natural history of left ventricular systolic 
function in AFD74.  We have long term follow up data on a large cohort of AFD patients 
allowing the description of the above and its relationship to symptoms.   
 
Arrhythmia 
The majority of adult patients with AFD will have abnormal resting ECGs, the most 
common abnormalities being voltage criteria for left ventricular hypertrophy and 
repolarisation abnormalities.  Short PR intervals, usually in the absence of an accessory 
pathway, AV conduction disease, sinus node disease and bundle branch block have also 
been described68, 77, 78.  Nevertheless, the importance of cardiac arrhythmia in the 
natural history of AFD is unknown.  I will describe the prevalence of arrhythmia in a 
prospectively studied cohort of patients with AFD, and determine its impact on clinical 
outcomes. 
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Pathogenesis 
Myocardial fibrosis has been described as a prominent feature of AFD cardiomyopathy, 
however there are little data regarding the pathogenesis of this and its relationship to 
symptoms and overall disease severity63.  I will investigate myocardial ischaemia and 
collagen turn over and their relation to symptoms and disease severity.   
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Summary of my role in the research project 
Together with Professor Perry Elliott, I developed the idea for the research project 
presented in this thesis and obtained funding for it.  I was responsible for recruiting 
patients into the project, and carried out the clinical and echocardiographic evaluation 
of patients recruited between 2002 and 2005.  I also retrospectively entered clinical 
and echocardiographic data onto the database for all patients recruited into the study, 
including all patients evaluated before 2002, by manually searching through patients’ 
medical records, echocardiograms and other investigations.  In addition, I modified the 
database so that data relevant to the AFD population could be entered and analysed.  I 
carried out all the analyses presented in this thesis. 
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Chapter 2 
 
Characterisation of cardiac 
arrhythmia  
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Abstract 
Background 
Over 60% of patients with AFD have symptoms and signs of cardiac involvement. The 
prevalence and clinical significance of arrhythmia in AFD are unknown. 
 
Methods and results 
The patient cohort comprised seventy-eight patients (43 male, 43.5 ± 15.0 years, 13.0-
83.0 years) with AFD, studied for a mean of 1.9 years (0.25-10 years).  All patients 
underwent clinical evaluation, 12-lead ECG and echocardiography.  Sixty patients 
(76.9%) underwent 24 hour ambulatory ECG (Holter) monitoring.  Atrial fibrillation (AF) 
was seen at baseline in 3/78 (3.9%) patients.  On Holter monitoring 8 (13.3%) had 
paroxysmal AF (PAF) and 5 (8.3%) had non-sustained ventricular tachycardia (NSVT).  
Patients with NSVT were all male with a maximal left ventricular wall thickness > 20mm.  
Univariate analysis identified age (p<0.001), left atrial diameter (p = 0.001), maximal 
left ventricular wall thickness (p = 0.003), left ventricular mass index (p = 0.009) and 
angina (p = 0.02) as predictors of AF/PAF.  Stepwise logistic regression identified age as 
the only independent predictor of AF/PAF (OR = 1.2, 95% CI = 1.1 to 1.3, p = 0.001).  
Four patients had pacemakers implanted for bradyarrhythmia and 1 had a bi-
ventricular pacemaker and internal cardioverter defibrillator implanted for heart 
failure and symptomatic NSVT.   
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Conclusion 
Brady- and tachyarrhythmias are common in older patients with AFD. Patients with AFD 
should undergo regular cardiological review, as the development of arrhythmia in these 
patients may have an impact on the natural history of this disease.  
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Aims 
The aims of this study were to determine the prevalence of cardiac arrhythmia in a 
large consecutively referred population of patients with AFD, and to assess their clinical 
significance. 
 
Methods 
Between January 1993 and December 2003, 78 patients (43 (55.1%) male; 35 (44.9%) 
female; mean age ( SD) = 43.5  15.0 years; range = 13-83) with AFD were assessed at 
The Heart Hospital, University College London, UK.  Patients were diagnosed with AFD 
on the basis of low plasma -Gal level and / or on mutational analysis.  Seven patients 
had been identified during the screening of patients with unexplained left ventricular 
hypertrophy 79. The remaining patients were direct referrals for cardiac evaluation from 
The Charles Dent Metabolic Unit, The National Hospital for Neurology and 
Neurosurgery and The Lysosomal Storage Disorders Unit, The Royal Free Hospital, 
London, UK.  Forty-one patients (6 female, 35 male) were on enzyme replacement 
therapy (ERT) at the base line visit. 
 
Clinical Assessment 
All patients underwent clinical history and examination.  Cardiac symptoms were 
defined as angina (central chest pain occurring during exertion, lasting for less than 15 
minutes), dyspnoea (graded using New York Heart Association criteria; NYHA), syncope 
and palpitation. 
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ECG Assessment 
All patients had a standard supine electrocardiogram (ECG) performed using a Hewlett-
Packard Page Writer, Andover, MA, USA.  ECGs were recorded at 25 mm/s with an 
amplitude of 1 mV/10mm and 50 Hz filtering.  The following features were recorded: 
Rhythm, PR interval and QRS duration. LVH was assessed using the Romhilt-Estes (RE) 
score 80.  A normal P-R interval was defined as > 120ms and ≤ 200ms.  A prolonged QRS 
duration was defined as > 120ms. 
 
Twenty-four hour ambulatory ECG (Holter) was performed in 60/78 (76.9%) patients 
using Reynolds Medical tape Holter monitors, Hertford, UK.  Non-sustained ventricular 
tachycardia (NSVT) was defined as three or more consecutive ventricular ectopics at a 
rate > 120 beats per minute lasting less than 30 seconds.  Atrial fibrillation (AF) was 
defined on the basis of the baseline ECG showing the replacement of consistent P 
waves by rapid oscillations or fibrillatory waves that vary in size, shape, and timing 81.  
Paroxysmal atrial fibrillation (PAF) was defined as episodes of AF lasting less than seven 
days, diagnosed from documented arrhythmia on 24 hour ambulatory ECG 82.  
Persistent AF was defined as AF lasting more than seven days, but potentially amenable 
to cardioversion82.  Permanent AF was defined as AF in which chemical/electrical 
cardioversion failed or was not attempted82. 
 
Echocardiography 
M-mode, 2D, and Doppler echocardiography were performed using a GE System V 
echocardiograph. The following left ventricular parameters were measured from M-
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mode tracings according to recommendations of the American Society of 
Echocardiography: end-diastolic left ventricular internal cavity diameter (LVed), 
interventricular septum thickness (IVS), posterior wall thickness (PW) and end systolic 
internal cavity diameter (LVes)83. The severity and distribution of left ventricular 
hypertrophy were assessed in the parasternal short-axis plane at the mitral valve and 
papillary muscle level. Maximum left ventricular wall thickness was defined as the greatest 
thickness in any single segment measured in diastole. Relative wall thickness (RWT) was 
calculated as ((IVS + PW)/LVed) assessed at the mitral valve level. Left Ventricular  
remodeling or left ventricular hypertrophy was defined as a RWT > 0.4583.  Left 
ventricular mass was calculated by the Devereux modified cube formula 83 and 
indexed by body surface area. Normal left ventricular mass index (LVMI) was defined 
as <134 gm/m2 for men and <110 gm/m2 for women 84.  Left ventricular geometry was 
classified as normal (normal LVMI and normal RWT), concentric remodelling (normal 
LVMI and increased RWT), eccentric left ventricular hypertrophy (increased LVMI and 
normal RWT), and concentric left ventricular hypertrophy (increased LVMI and 
increased RWT). Fractional shortening (FS) ((LVed-LVes/LVed)*100) was used to 
measure systolic performance85.   
 
Follow Up  
Follow-up started with the date of the baseline cardiovascular assessment.  Data were 
collected at routine clinic visits, and where necessary by direct communication with 
patients, their attending physicians and patients' general practitioners; all data were 
verified by the author.  
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Statistical Analysis 
Statistical analysis was performed using SPSS v19.0.   The χ2 test was used to compare 
non-continuous variables.  Continuous variables were tested for normality, non-
normally distributed variables were tested using the Wilcoxon Rank sum and normally 
distributed variables compared using the 2-tailed independent sample Student’s t-test.  
All values are expressed as means  standard deviation.  Statistical significance was 
defined as p < 0.05.   
 
Results 
Clinical Evaluation 
Table 2.1 describes the prevalence of cardiac and AFD symptoms separated by gender.  
Table 2.2 displays the important findings in the baseline electrocardiographic and 
echocardiographic findings for this cohort.  There were no differences between males 
and females in the prevalence of cardiac symptoms.  Men were more likely to suffer 
from AFD symptoms and signs compared to women. 
 
ECG Changes at Baseline 
There were no significant differences between men and women in the baseline heart 
rate, QRS axis or P-R interval.  The mean RE score was greater (mean difference = 2.8, 
95% CI = 1.7 to 4.0, p = <0.001) and the mean QRS duration was greater (p < 0.001) in 
men compared to women (see Table 2.2).  Two males had evidence of pre-excitation 
on their baseline ECG.  One of these patients had an intracardiac Electrophysiological 
study.  No accessory pathway was identified; however there was accelerated AV 
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conduction with a fixed HV time of less than 10ms and normal decremental AV and VA 
conduction.  The second patient went into complete heart block and there was 
evidence of a presumed accessory pathway on his Cardiomemo ECG as demonstrated 
by a pre-excited QRS complex followed by a normally conducted QRS complex (Figure 
2.1).  Three of the 78 patients had AF (3.9%; 2 persistent and 1 permanent).  There was 
no difference in the prevalence of AF in patients on ERT compared to those not on ERT.  
 
Holter assessment at baseline 
Sixty patients underwent Holter assessment at the baseline visit.  Eight of the 60 
patients (13.3%) had PAF (lasting less than 24 hours).  Five of the 60 patients (8.3%) had 
NSVT.  There was no difference in the prevalence of AF/PAF between males and 
females. There seemed to be no difference in the prevalence of PAF/NSVT on Holter 
between patients on ERT and those not on ERT.  There was a significant increase in the 
prevalence of arrhythmia with age (Figure 2.2a and b). 
 
Echocardiographic Parameters at Baseline 
Compared to females, males had greater maximal left ventricular wall thickness 
(mean difference = 3.6mm, 95% CI = 1.6, 5.6mm, p = <0.001), larger LVed (mean 
difference =3.9 mm, 95% CI = 1.6, 6.2mm, p = 0.001) and higher LVMI (p < 0.001, see 
Table 2.2).  There was a trend to a larger LA size and LVes in men compared to 
women (p = 0.07 and p = 0.08 respectively; Table 2.2).   
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Table 2.1: Symptoms at Baseline Evaluation in Males and Females 
 
 
 All (n=78) Female (n=35) Male (n=43) p-value 
Chest Pain 15 (19%) 8 (23%) 7 (16%) 0.57 
Dyspnoea*  22 (28%) 7 (20%) 15 (36%) 0.21 
Palpitations 22 (28%) 10 (29%) 12 (28%) 1.0 
Syncope 6 (8%) 2 (6%) 4 (9%) 0.7 
Acroparaesthesiae 45 (58%) 14 (40%) 31 (72%) 0.005 
Hypohydrosis 24 (31%) 5 (14%) 19 (44%) 0.006 
Angiokeratoma 27 (35%) 4 (11%) 23 (54%) <0.001 
Abdominal Pain 22 (28%) 6 (17%) 16 (37%) 0.048 
Tinnitus 15 (19%) 1 (3%) 14 (33%) 0.001 
 
 
Table 2.1 Legend: * = New York Heart Association class II and above. 
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Figure 2.1: Complete heart block 
  
 
 
 
 
 
Figure 2.1 Legends:  Cardio-memo strip showing complete heart block in a 55-year-old male patient requiring permanent pacemaker implantation. *Conducted beat 
showing pre-excitation.  **Conducted beat shows a normal PR interval. 
* ** 
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There was no correlation between the PR interval and echocardiographic parameters; 
QRS duration correlated with maximal left ventricular wall thickness (r = 0.4, p = 0.001), 
LVMI (r = 0.5, p < 0.001), LVed (r = 0.3, p = 0.003) and LVes (r = 0.3, p = 0.01). 
 
Clinical predictors of arrhythmia 
All five patients with NSVT were male (mean age 58.4  15.1 years, range 46-83).  Three 
of the five patients with NSVT had symptoms of pre-syncope or syncope and all five 
had symptomatic palpitations.  When compared to the rest of the cohort, the presence 
of syncope was associated with the presence of NSVT (OR = 24.5, 95% CI = 2.9, 207.3, 
p = 0.006), similarly the presence of palpitations was associated with NSVT (OR = 1.4, 
95% CI = 1.04, 1.3, p = 0.003).  This relationship was not present in patients with AF/PAF.  
Three of the five patients with NSVT had a QRS duration > 120ms.  All five patients had 
a maximal left ventricular wall thickness ≥ 20mm and a LA size > 40mm (mean = 51.2 ± 
9.7).  The mean LVMI was 243.6 ± 102.3 gm/m2 (range = 162.0 to 406.9).  All the patients 
with NSVT had angiographically normal coronary arteries. 
 
Univariate analysis identified age (p<0.001), LA size (p = 0.001), maximal left ventricular 
wall thickness (p = 0.003), LVMI (0.009) and a history of angina (p = 0.016) as predictors 
of AF and/or PAF.  Stepwise logistic regression analysis identified age as the only 
independent predictor of atrial fibrillation (OR = 1.2, 95% CI = 1.1, 1.3, p = 0.001).  
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Table 2.2: Baseline Evaluation Indices in Males and Females 
 All (n=78) Female (n=35) Male (n=43) p-value 
Age (years) 43.5 ± 15.0 46.7 ± 15.6 40.7 ± 14.1 0.08 
Heart Rate (beats per minute) 64.9 ± 14.8 67.2 ± 12.2 62.9 ± 16.4 0.2 
PR Interval* (ms) 144.1 ± 26.5 149.3 ± 29.4 139.7 ± 23.2 0.12 
PR  120ms  16 (21%) 5 (5%) 11 (27%) 0.36 
PR > 200ms (%) 3 (4%) 2 (6%) 1 (2%) 0.36 
QRS Duration (ms) 98.6 ± 19.7 90.1 ± 17.2 105.5 ± 19.0 <0.001 
QRS Duration >120ms 12% 6% 16% 0.18 
Romhilt-Estes Score 4.0 ± 2.9 2.4 ± 2.8 5.3 ± 2.2 <0.001 
Maximum LV Wall Thickness (mm) 13.8 ± 4.7 11.7 ± 3.4 15.3 ± 5.0 <0.001 
Left Atrial Diameter* (mm) 38.8 ± 6.7 37.2 ± 5.4 40.0 ± 7.5 0.07 
End Diastolic LV Diameter (mm) 47.7 ± 5.4 45.5 ± 4.4 49.4 ± 5.6 0.001 
End Systolic LV Diameter* (mm) 29.1 ± 4.9 28.2 ± 3.7 29.9 ± 5.6 0.08 
Fractional Shortening (%) 39 ± 7 38 ± 7 39 ± 7 0.55 
LV Mass Index* (g/cm2) 134.7 ± 56.7 103.8 ± 23.8 158.9 ± 63.0 <0.001 
 
Table 2.2 Legend: Values expressed as mean ± standard deviation or %, * denotes variables 
with non-normal distribution, analysed using Wilcoxon Rank sum.  LV = Left Ventricular. 
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Figure 2.2a:  Age adjusted prevalence of arrhythmia in Anderson-Fabry Disease in Males 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2a Legends: Age adjusted (age in tertiles) prevalence (%) of atrial fibrillation (AF), paroxysmal AF and non-sustained ventricular tachycardia (VT). 
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Figure 2.2b:  Age adjusted prevalence of arrhythmia in Anderson-Fabry Disease in Females 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2b Legends: Age adjusted (age in tertiles) prevalence (%) of atrial fibrillation (AF), paroxysmal AF and non-sustained ventricular tachycardia (VT).
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Follow-Up  
Follow up data were available in 66/78 (84.6%) patients.  The mean follow up time was 
1.9 years (range = 3 months – 10 years).  During follow up, 7/66 (10.6%) patients had 
permanent pacemakers implanted; 1 for complete heart block; (patient with pre-
excitation, Figure 2.1); 3 for symptomatic bradycardia; 1 for symptomatic LV outflow 
tract gradient reduction; 1 for complete heart block post alcohol septal ablation (the 
latter two patients had been followed-up with a presumed diagnosis of hypertrophic 
cardiomyopathy for several years prior to the diagnosis of AFD); 1 had a bi-ventricular 
device and internal cardioverter defibrillator for heart failure and symptomatic NSVT 
(Figure 2.3). 
 
There were 2/66 (3.0%) new cases of persistent AF, one patient with persistent AF at 
baseline evaluation had been successfully cardioverted to sinus rhythm and one 
remained in permanent AF.  There were 2 new cases of PAF documented. 
 
Discussion 
This study shows that arrhythmia is common in patients with AFD and that it is 
associated with significant morbidity.   
 
Population based studies have shown that the overall prevalence of atrial fibrillation 
in the normal population is less than 1% 86; this prevalence is age dependent, with a 
prevalence of less than 1% in people less than 55, rising to 9% or more in the over 
eighties 86. 
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Figure 2.3: Non-Sustained Ventricular Tachycardia 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 legend:  Twenty-four hour ambulatory ECG recording of symptomatic 6 beat non-sustained ventricular tachycardia in a 59-year-old male patient requiring 
internal cardioverter defibrillator implantation.
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In this study, the overall prevalence of AF was four times higher than in the general 
population; in the over fifties it was present in 12%. This suggests that AFD is associated 
with a substantial risk of AF in middle aged and elderly patients. 
 
Gender related differences 
Although AFD is an X-linked disorder, most females who carry a pathogenic mutation 
in the -Gal gene develop signs and symptoms of the disease, albeit at an older age 
than men 68.  A striking observation in this study was that, in spite of a higher incidence 
of “classical” signs and symptoms such as angiokeratomata, neuropathic pain and 
hypohidrosis in men, the incidence of cardiovascular symptoms was similar in males 
and females.  Men tended to have a longer QRS duration and higher Romhilt-Estes 
score than women, reflecting their greater left ventricular mass.  Similarly, all the 
patients with NSVT were men; there was, however, no gender related difference in the 
frequency of AF, the only independent risk factor being age.  It is likely, therefore, that 
most patients with AFD become prone to cardiac disease and arrhythmia if they live 
into middle age and beyond. 
 
Clinical Implications 
The impact of arrhythmia on mortality in patients with AFD cannot be determined from 
this study, but the high prevalence of atrial fibrillation, the occurrence of complete 
heart block and symptomatic ventricular tachycardia, suggests that it may contribute 
to the shortened life expectancy of patients with this disease.  This observation 
suggests that all patients with AFD should undergo regular assessment with ECG and 
Holter monitoring.   
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Patients with AFD have a higher incidence of stroke that is usually attributed to 
microvascular dysfunction87-89.  Additionally, an increased thrombotic potential, 
dilative arteriopathy and changes in regional cerebral hyperperfusion may contribute 
to cerebrovascular disease in patients with AFD49-51.  Lenders et al suggest that up to 
7% of patient with AFD also carry a mutation in the Factor V Leiden gene.  These patient 
have a 5 fold increase (95% CI HR = 2-13) in the risk of suffering a thromboembolic 
event90.  The high prevalence of atrial arrhythmia in this study, suggests that 
thromboembolism may be an additional risk factor for stroke, and consideration of 
anticoagulation in patients with permanent or frequent paroxysms of AF may be 
needed. Unfortunately, the early age of onset of atrial arrhythmia compared to the 
general population precludes the use thromboembolism risk scores such as the 
CHA2DS2-VASc scoring system in this patient group91. 
 
There has been no systematic study of sudden death in AFD.  To date, there have been 
four case reports published describing the unexpected death of patients with AFD.    
Three were asymptomatic elderly females (diagnosed at post-mortem) 92, 93, one was a 
26-year-old male known to have AFD who died whilst running 94; and one was a male 
known to have AFD who had ventricular fibrillation resistant to defibrillation 95.  Three 
of the four patients had post-mortem evidence of significant cardiomyopathy with 
hearts weighing >450gms.  All the patients with NSVT in our study had evidence for 
significant cardiac disease (all male, increased LVMI and maximal left ventricular wall 
thickness > 20mm).  Together these data suggest that sudden death in AFD is associated 
with significant cardiac involvement and may be related to NSVT.   
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Conclusions 
This study demonstrates that arrhythmias are common in older patients with AFD.  
This, together with the high prevalence of permanent pacemaker implantation, 
suggests that there is a need for regular cardiology follow-up in this patient group, 
monitoring for rhythm abnormalities.  
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Chapter 3 
 
The natural history of left 
ventricular systolic performance  
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Abstract 
Aim 
Although AFD cardiomyopathy is usually associated with left ventricular hypertrophy, 
conduction disease and valvular thickening, a recent study has demonstrated an 
impairment of contractile function as well.  The aim of this study was to determine the 
importance of systolic function in the natural history of AFD. 
 
Methods and results 
Twelve patients 9 male, (aged; 54.5 ± 12.2) years; minimum = 42 and maximum = 82) 
with AFD were studied. All patients underwent clinical, electrocardiographic and 
echocardiographic evaluation. Two echocardiograms >1 year apart were performed on 
all patients. Patients on enzyme replacement therapy (ERT) were excluded from the 
study. 
 
The mean follow up between echocardiograms was 3.3 ± 2.7 years (minimum = 1, 
maximum = 9). There was no change in left ventricular mass. There was an increase 
in the end systolic left ventricular diameter of 5.0mm (95% confidence interval (CI) = 
0.2, 9.6, p = 0.038) and a decrease in fractional shortening of 6.1% (95% CI = 0.3, 11.9, 
p=0.042). Three patients (25%) developed symptomatic congestive heart failure. 
 
Conclusions 
Systolic impairment in patients with AFD cardiomyopathy is common. The decline in 
systolic function may represent a measure of disease severity and provide a clinically 
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important surrogate marker for response to therapy. 
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Aims 
The aim of this study was to determine the importance of systolic performance in the 
natural history of AFD and its potential value as marker of disease progression, we 
performed a retrospective analysis of an untreated cohort of patients followed for at 
least one year. 
 
Methods 
A total of 75 patients with AFD recruited from The Heart Hospital, London, The Royal Free 
Hospital and The National Hospital for Neurology and Neurosurgery, were evaluated 
between 1st January 1993 and 1st December 2003. Diagnosis was based on low 
plasma α-Gal levels and on genetic mutational analysis. The mean (standard 
deviation) follow up from diagnosis of AFD was 5.8 ± 4.8 years. Of the 75 patients 24 
had been followed up for more than one year and 12 were receiving ERT at the time 
of evaluation. The final study cohort comprised 12 untreated patients (9 male, 3 
female patients mean age 54.5 ± 12.2 years; minimum age = 42, maximum = 82) with 
at least 2 echocardiograms separated by one year or more. Six patients were detected 
during screening of unexplained hypertrophic cardiomyopathy (HCM)79, the remaining 
six were patients referred for cardiac assessment of patients with AFD. 
 
Clinical assessment 
All patients underwent clinical examination, supine 12-lead electrocardiography (ECG) 
(Hewlett-Packard, USA) and 24 hour ambulatory ECG (Reynolds Medical, UK) 
monitoring as described in chapter 2. 
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Plasma α-Gal analysis 
Plasma α-Gal activity was measured with the fluorogenic substrate 4-
methylumbelliferyl-α-Dgalactopyranoside (Sigma), with N-acetyl-D-galactosamine 
(Nacalai Tesque) used as an inhibitor of α-N-acetylgalactosaminidase as described 
previously 96. On the basis of previously published data, a plasma α-Gal activity of 1.2 
nmol·h–1·mL–1 was considered diagnostic of AFD 96.  All patients with diagnostic plasma 
α-Gal levels went on to have confirmation of their diagnosis with genetic mutational 
analysis. 
 
Assessment of left ventricular mass and function 
M-mode, 2D, and Doppler echocardiographic assessment of all patients was as previously 
described in chapter 2 using a GE System V echocardiograph.  
 
Statistical analysis 
Statistical analysis was performed using SPSS v19.0 (Chicago, USA). The χ2 test was 
used to compare non-continuous variables, and the 2-tailed paired sample Student’s 
t-test was used to compare continuous variables. All values are expressed as means ± 
standard deviation. Statistical significance was defined as p 0.05. 
 
Results 
Table 3.1 describes the baseline symptoms and echocardiographic findings in this 
cohort. The mean time between the analysed echocardiograms was 3.3 ± 2.7 years 
(minimum = 1, maximum = 9). 
 
Four patients (41%) had two symptoms or signs of AFD, and one in retrospect had 4 
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symptoms or signs of AFD. Ten patients (83%) presented with a cardiovascular 
symptom. Six patients (50%) had two or more cardiac symptoms (see table 3). 
During the follow up, 2 (17%) patients had documented non-sustained ventricular 
tachycardia; one (8%) had an internal cardiac defibrillator implanted prophylactically for 
this. Four (33.3%) patients required permanent pacemaker implantation: two for 
symptomatic bradycardia; one for congestive heart failure (bi-ventricular device); and 
one patient for complete heart block following alcohol septal ablation prior to the 
diagnosis of AFD. Two other patients progressed to congestive heart failure. 
 
Electrocardiography 
The baseline mean P-R interval was 141.5 ± 22.3 ms with a baseline mean QRS duration 
of 112.7 ± 25.0 ms. During follow up, no difference in the P-R interval was seen. There 
was an increase in the QRS duration (mean = 14.2ms; 95% CI = 4.0, 24.4ms, p = 0.012). 
Patients with pacemakers were excluded from this analysis. 
 
Echocardiography 
Three patients (25%) had normal left ventricular wall thickness, eight (66.7%) had 
concentric LVH and one patient (8.3%) had distal LVH. Figures 3.1 & 3.2 plot the changes 
in LVes, LVed and FS in individual patients. There was an increase in the LVes (mean 5 
± 6.9 mm, 95% CI = 0.2, 9.6, p=0.038), accompanied by a reduction in the FS (mean 6.1 
± 8.7 mm, 95% CI = 0.3, 11.9 mm, p=0.042) and a trend towards an increasing LVed 
(mean 2.9 ± 5.4, 95% CI = -0.5, 6.35 mm, p=0.088). The rate of dilatation in the left 
ventricular end systolic dimension was 1.9mm/year with an associated decline of 2.7 
%/year in the fractional shortening. There was no correlation between age and 
baseline LVes. 
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Table 3.1: Anderson-Fabry Disease Symptoms and Baseline Echocardiographic Findings 
 
 
Table 3.1 legend: α-Gal = α-Galactosidase, Angina = Exertional chest pain, Dyspnoea expressed as New York Heart Association dyspnea class, LV = Left Ventricular.  
SEX AGE Mutation 
Plasma 
-Gal 
Level 
Leukocyte 
-Gal 
Activity 
Angina Dyspnoea Syncope Palpitations 
Maximum LV 
Wall Thickness 
(mm) 
LV End 
Systolic 
Dimension 
(mm) 
LV End 
Diastolic 
Dimension 
(mm) 
Fractional 
Shortening 
(%) 
M 46 Asn215Ser 0.99 7.4 - 1 - + 24 30 52 42 
M 82 Asn215Ser 0.25 4.7 + 2 - + 26 25 38 34 
F 75 Deletion 4.30 84.0 - 1 - - 11 25 41 39 
M 50 Asn215Ser 0.28 5.4 + 2 - + 24 19 35 46 
M 58 Ile317Thr 0.04 5.2 + 2 - + 21 33 50 34 
F 45 520delT 1.6 N/A + 1 - - 10 30 50 40 
M 53 Deletion 0.64 1.8 - 1 - + 20 27 53 49 
M 49 Asn215Ser 0.77 7.8 + 2 - - 14 26 44 41 
M 46 Arg301Gln 0.10 3.6 - 1 + + 20 21 43 51 
M 55 Ile317Thr 0.40 3.1 - 1 - - 24 31 50 38 
F 53 Deletion 3.90 63.0 + 2 - - 11 24 45 47 
M 42 Gly361Arg 0.31 2.2 - 2 - - 24 21 46 54 
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There was a negative correlation between plasma (and leukocyte) α-Gal and baseline 
maximal LV wall thickness and LV mass index (r = - 0.6, p = 0.045; r = - 0.6, p = 0.033 
respectively). There were no correlations between α-Gal levels and baseline LV cavity 
dimensions. Similarly there were no correlations between enzyme levels and any 
changes in these dimensions during follow up. 
 
Three patients demonstrated a reduction in LVes during follow-up. One patient had a 
6mm reduction in the LVes dimension and an 11% increase in the FS. This patient 
was a 45 years old female. During follow up, she developed a 5mm increase in LV wall 
thickness and a change in her LV geometry from normal to concentric LVH. There were 
no changes to medications or in symptoms. The other two patients had 2mm 
reductions in LVes. These reductions were associated with a 1% reduction in FS in one 
patient and an increase of 4% in the other. 
 
The baseline mean RWT was 0.71 (0.21) (range 0.38-1.16). One patient (female) had 
normal LV geometry at baseline, eight (66.7%) had concentric LVH and three (25%) had 
concentric remodeling. Of the three patients with concentric remodeling, one 
progressed to concentric LVH; one to normal geometry and one had no change on 
follow up. Of the 8 patients with concentric LVH at baseline, 1 patient regressed to 
concentric remodeling, 1 patient developed eccentric LVH and 6 patients remained 
unchanged at follow up. 
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Figure 3.1:  The Change in Left Ventricular End Systolic Diameter, and Left Ventricular End Diastolic Diameter During Follow Up 
Figure 3.1 legend:  Error bars represent mean (SD) for baseline and follow-up respectively: Left Ventricular End Systolic Diameter (mm); 26.5(4.4), 31.5(7.0): Left 
Ventricular End Diastolic Diameter (mm); 45.6(5.7), 48.5(5.7). 
Figure 3.2:  The Change in Fractional Shortening During Follow Up 
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Figure 3.2 legend: Error bars 
represent mean (SD) for baseline and follow-up respectively: Fractional Shortening (%); 42.9(6.5), 36.1(8.6).
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Discussion 
This study demonstrates that left ventricular systolic function progressively 
deteriorates in patients with AFD. Importantly, the change in systolic performance was not 
accompanied by a change in left ventricular mass index.  This suggests that systolic 
function may be a sensitive surrogate marker of disease severity and prognosis in 
patients with AFD cardiomyopathy. 
 
Cardiac disease in AFD 
The most commonly reported cardiac abnormalities in patients with AFD include 
increased QRS voltage and repolarisation changes, short PR interval, QRS prolongation, 
concentric left ventricular hypertrophy and valvular thickening 77, 97, 98. Previous isolated 
case reports have reported congestive cardiac failure from restrictive cardiomyopathy 
and LV dilatation, with one case requiring cardiac transplantation62, 99-103.  
 
To the best of our knowledge, this is the first time that the deterioration in systolic 
dysfunction and progression to congestive cardiac failure has been reported in a 
prospectively studied cohort of patients with AFD. 
 
Mechanism of systolic dysfunction 
Although the genetic and biochemical basis of AFD is well described, the pathophysiology 
of cardiac disease in AFD is inadequately understood. Histologically, AFD is 
characterised by myocyte vacuolation and intralysosomal inclusions on electron 
microscopy 97. However, the consequences of these abnormalities on myocyte 
function are not known. Moreover, some data suggest that substrate accumulation 
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accounts for only 3% of the increased LV mass seen in AFD patients 62. Patients with 
AFD have areas of interstitial expansion on gadolinium enhanced cardiac magnetic 
resonance imaging 63. It is unclear whether this is a primary or secondary 
phenomenon, but the presence of interstitial abnormalities suggest that progressive 
fibrosis may also contribute to the reduction in systolic performance observed in this 
study. 
 
Clinical implications and limitations 
Our study suggests that systolic function may be a surrogate marker of disease severity 
in AFD. Weidemann et al have recently shown that enzyme replacement therapy using a 
recombinant α-galactosidase A preparation improves longitudinal and radial strain rate 
in patients with AFD 74. Strain rate imaging is a new technique that quantifies changes 
in regional myocardial deformation, and is thought to be a sensitive measure of 
myocardial function 104. Our findings and Weidemann et al study support the 
hypothesis that systolic function may also be a useful surrogate end-point with which 
to assess the response to treatment.  This study is limited by the small size of the cohort 
and the relatively simple assessment of systolic function.  
 
Conclusions 
This study suggests that cardiac systolic dysfunction is common in patients with AFD 
and hence systolic performance should be monitored in all patients with AFD.   
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Chapter 4 
 
Exercise capacity 
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Abstract 
Background  
Patients with AFD frequently complain of exercise limitation, but few studies have 
quantified its severity and relation to disease severity. 
  
Methods and Result  
Cardiopulmonary exercise testing (CPET) was performed in 103 consecutive patients 
(mean age 43.2±14.8 years, 53 (51.5% male) with AFD; the relation between gas 
exchange parameters, cardiovascular manifestations and other markers of disease 
severity was determined. Oxygen consumption at peak exercise (pVO2) was less than 
80% of predicted maximum (%VO2max) in 51 patients (33 (64.7%) male, 18 (35.3%) 
female; p=0.01). Males had lower % predicted VO2max (p=0.001), % predicted peak 
work rate (p<0.001), and anaerobic threshold (p=0.04) when compared to females. 
Stepwise linear regression identified Mainz severity score index (MSSI) score as the only 
independent predictor of % predicted VO2 max (β=-1.02, p<0.001). 
 
Conclusions  
Males with AFD have more severe exercise limitation when compared to females. The 
utility of pVO2 as a surrogate marker of disease severity warrants further investigation. 
 
Aim 
Many patients with AFD die prematurely in the fourth and fifth decade of life from 
stroke, heart failure and renal failure, but throughout life, experience fatigue and 
exercise limitation 105. The aim of this study was to determine exercise capacity using 
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symptom limited cardiopulmonary exercise testing (CPET) in a large referral population 
of patients with AFD and its relation to markers of disease severity.  
 
Methods 
One hundred and eleven consecutively referred patients (mean age 43.0±15.6 years; 
56 (50.5%) males) with AFD were assessed at the Heart Hospital, University College 
Hospitals, London, between January 1993 and February 2005. The diagnosis of AFD was 
based on plasma A-Gal levels and mutational analysis. Sixty-two patients (55.9%, 44.9 
(12.4) years, 45 (81.8%) males) were receiving enzyme replacement therapy. All 
patients underwent clinical history and physical examination. The following cardiac 
symptoms were noted: angina (exertional central chest pain lasting ≤15 minutes); 
dyspnoea (graded using New York Heart Association criteria, NYHA); syncope and 
palpitation.  
 
All patients underwent clinical examination, supine 12-lead electrocardiography (ECG) 
(Hewlett-Packard, USA) and 24 hour ambulatory ECG (Reynolds Medical, UK) 
monitoring as described in chapter 2. 
 
Mainz severity score index (MSSI) 
In brief, the MSSI scoring system comprises four components: general, neurological, 
cardiovascular, and renal106. Each component consists of a group of signs and 
symptoms associated with AFD, weighted according to their contribution to morbidity. 
For each sign and symptom, a score is assigned and summed to produce a total score 
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for that system component. These individual component scores are then totaled to give 
the final MSSI score (Table 4.1).  
 
Cardiopulmonary testing 
Patients were exercised in the upright position using a bicycle ergometer (Ergometrics 
800S, SensorMedics, Inc., Yorba Linda, California, USA) with continuous 12-lead 
electrocardiographic monitoring (Max 1, Marquette Electronics Inc., Milwaukee, 
Wisconsin). 
 
Breath-by-breath respiratory gas sampling was performed using a VMax 229 Console, 
(SensorMedics, Inc). Patients were exercised using a 10 to 25 W/min incremental ramp 
protocol adjusted to patients’ subjective assessment of their exercise capacity. Patients 
cycled at a constant rate of 60 to 65 rpm to the point of maximum effort. Respiratory 
gases were sampled continuously from a mouthpiece and analyzed using a 1111D/000 
paramagnetic transducer for oxygen and a 2900 MMC non-dispersive infrared sensor 
for carbon dioxide.  
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Table 4.1 : Mainz Severity Score Index 
 
Mainz Severity Score Index 
General Neurological Cardiovascular Renal 
Symptom/Sign Score Symptom/Sign Score Symptom/Sign Score Symptom/Sign Score 
Facial 
appearance 
0/1 Tinnitus 0/1/2 LVH 
0/1/6/
8/12 
Renal 
involvement 
0/4/8
/12/1
8 
Angiokeratom
a 
0/1/2 Vertigo 0/1/2 
Valve 
abnormalities 
0/1   
Oedema 0/1 Acroparaesthesiae 0/3/6 
ECG 
abnormalities 
0/2   
Musculoskelet
al 
0/1 Pyrexia pain crisis 0/2 Pacemaker 0/4   
Cornea 
verticillata 
0/1 Cerebrovascular 
0/1/3/
5 
Hypertension 0/1   
Sweating 0/1/2 Depression 0/1     
Abdominal 
Pain 
0/2 Fatigue 0/1     
Altered Bowel 0/1 
Reduced activity 
level 
0/1     
Piles 0/1       
Airways 
disease 
0/2       
NYHA 
0/1/2/
3/4 
      
Max Score  
18 
Max Score  
20 
Max Score 
20 
Max Score 
18 
 
 
Table 4.1 legend: Adapted from Whybra et al 106. NYHA = New York Heart Association 
dyspnoea class; LVH = left ventricular hypertrophy, points for ECG and echocardiographic 
evidence of LVH; Neurological component has points for computed tomography / magnetic 
resonance imaging abnormalities, history of transient ischemic attack; Renal component 
includes reduced glomerular filtration rate / creatinine clearance and end stage renal failure 
and dialysis.  
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The signals underwent analogue to digital conversion for the calculation of oxygen 
consumption (VO2) and carbon dioxide output (VCO2) using an established technique107, 
108. A printout of VO2 (l/min), VCO2 (l/min), heart rate (HR) (beats per min), work rate 
(W) and respiratory quotient (RQ) was obtained and averaged at 10 s intervals to obtain 
smooth graphical representation. Plots of VCO2 against VO2 were used to estimate 
anaerobic threshold (AT). Blood pressure was recorded at 2-minute intervals during 
exercise and for 10 minutes into recovery using a brachial cuff and 
sphygmomanometer. Change in blood pressure (defined as peak exercise SBP – pre-
exercise SBP) was recorded. All tests were supervised by an experienced senior 
physiologist. 
 
The following calculations were made:  
1. Peak oxygen consumption (pVO2) was defined as the highest oxygen consumption 
achieved during exercise. This was the highest measured VO2 value over the last 10 s 
of exercise. Data were presented as values normalized for body weight (ml/kg/min). 
The predicted maximal oxygen consumption (VO2 max) was calculated using 
established equations based on age and gender109, 110. The normalized value was then 
expressed as a percentage of the predicted maximum value. Values <80% were 
considered abnormal because they fall below previously established 95% confidence 
limits 111. 
 
2. Anaerobic threshold is the VO2 above which aerobic energy production is 
supplemented by anaerobic mechanisms and is reflected by an increase in lactate and 
lactate/pyruvate ratio in the muscle and arterial blood 111 21. This can be estimated 
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noninvasively by plotting VCO2 versus VO2 (“V slope method”; 112. The AT was expressed 
as a percentage of the predicted VO2 max. Values<40% predicted VO2 max were 
considered abnormal 112.  
 
3. Oxygen pulse (O2P) is the ratio of VO2 to heart rate (HR) (equation 1). It is the product 
of stroke volume (SV) and the systemic arteriovenous oxygen difference (A-V) O2 
(equation 2). 
O2P=VO2/HR (1) 
VO2 max=Cardiac output×(A-V) O2  
Cardiac output=SV×HR 
O2P=SV×(A-V) O2. (2) 
 
Values were expressed as a percentage of the maximum predicted O2P calculated from 
equation 1 using established formulae for predicted VO2 max 109, 110 and predicted 
maximum heart rate 113, 114. Values >80% predicted VO2 max were regarded as normal 
if the individual had achieved a maximal heart rate of at least 80% to exclude 
chronotropic incompetence, because this is associated with falsely high readings 113, 114. 
 
Statistical analysis 
Statistical analysis was performed using SPSS v19.0 (SPSS, Inc., Chicago, Illinois, USA). 
Analyses were stratified for gender. The chi-square test was used to compare non-
continuous variables and the two-tailed, independent-samples student t test was used 
to compare continuous variables. All values were expressed as mean ± SD. Stepwise 
linear regression analysis was used to identify independent predictors of pVO2 using 
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those variables significantly associated with pVO2 in a univariate analysis. Statistical 
significance was defined as p <0.05. 
 
Results 
CPET data were unavailable in 8 (7 %) of the 111 patients. The reasons were as follows: 
3 patients were less than 16 years of age (all female); 1 was 80 years of age (female); 2 
were wheelchair bound (of which one was male); 1 had fast atrial fibrillation at 
presentation (male) and 1 refused testing (female).  
 
Baseline characteristics of the final study cohort (n=103) are shown in Table 4.2. Males 
had a higher prevalence of AFD symptoms and higher MSSI scores compared to females 
(mean difference = 13.0, 95% CI = 8.5, 17.4, p < 0.001). Males tended to have higher 
levels of proteinuria and lower glomerular filtration rates when compared to females 
(Table 4.2). 
 
Cardiac disease 
Cardiac findings in males and females are summarized in Table 4.3. There was no 
difference in the prevalence of cardiovascular symptoms between males and females. 
Males tended to have lower resting heart rates compared to females (mean difference 
= 5.5 bpm, 95% CI = -0.1, 11.1; p = 0.05). The QRS duration was greater in males 
compared to females (mean difference = 15.7 ms, 95% CI = 8.4, 23.0; p < 0.001). Males 
had a higher RE score compared to females (mean difference = 2.6, 95% CI = 1.5, 3.7; p 
< 0.001, Table 4.2).  
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Table 4.2: Anderson - Fabry Disease Symptoms and Signs Stratified By Gender  
 
 
 Females (n = 50) Males (n = 53) Significance 
Age (Years) 45.4 (15.4) 41.2 (14.1) 0.2 
Plasma A-Gal levels (nmol/hr/ml) 3.8 (1.4) 0.6 (0.9) <0.001 
Enzyme replacement therapy (%) 16 (27.1) 43 (79.3) <0.001 
MSSI score 18.5 (10.3) 31.5 (11.9) < 0.001 
Acroparasthaesia (%) 23 (46.0) 42 (64.6) 0.002 
Hypohidrosis (%) 13 (26.0) 27 (50.9) 0.02 
Abdominal pain (%) 16 (32.0) 23 (43.4) 0.4 
Tinnitus (%) 5 (10.0) 20 (37.7) 0.002 
Angiokeratomata (%) 7 (14.0) 34 (64.2) <0.001 
Glomerular filtration rate (ml/min/m2) 89.3 (23.8) 80.8 (27.5) 0.2 
Proteinuria (g/24hr) 0.2 (0.2) 0.3 (0.4) 0.1 
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Males had greater maximal left ventricular wall thickness (p<0.001), greater left 
ventricular dimensions (p<0.001 for LVed and p=0.04 for LVes) and greater left 
ventricular mass index (p<0.001). 
 
Exercise capacity in males and females 
Metabolic exercise data for males and females are shown in Table 4.4. Males had a 
lower peak exercise oxygen consumption compared to females (mean difference = 
16.1% 95% CI = 7.0, 25.3; p = 0.001).  
 
There was a trend for more males to have an abnormal pVO2 (< 80%) compared to 
females (33 (62.3%) versus 18 (36%) respectively; RR = 1.7, 95% CI = 1.5, 2.5; p = 0.01). 
There were no differences in pVO2 in patients receiving ERT compared to those not 
receiving ERT. The amount of work performed by males during exercise was less when 
compared to females (mean difference = 19.6%, 95% CI = 9.3, 29.9; p < 0.001) despite 
similar respiratory quotients. Males had a lower anaerobic threshold compared to 
females (mean difference = 3.9, 95% CI = 0.2, 7.7; p = 0.04); the number of males and 
females with abnormally low anaerobic thresholds was similar (25 (52.1%) versus 
16(34.8%), respectively; p = 0.1).  More men than women had a peak HR response of 
less than 80% of their predicted value at peak exercise, 30 (56.6%) versus 18 (36.0%), 
RR = 1.5, (95% CI = 1.0, 2.1; p = 0.048). 
 
Despite the lower peak exercise heart rates, males had a lower oxygen pulse compared 
to females (mean difference = 10.3%, 95% CI = 0.6, 20.0; p = 0.04).  
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Table 4.3: ECG and Echocardiographic Data Stratified By Gender 
 
  
 Females (n = 50) Males (n = 53) Significance 
Cardiac symptoms    
Angina (%) 9 (18.0) 10 (18.9) 1.0 
Dyspnoea (NYHA ≥ 2, %) 9 (18) 17 (32.1) 0.2 
Palpitations (%) 13 (26.0) 13 (24.5) 1.0 
Syncope (%) 3 (6.0) 4 (7.5) 1.0 
    
ECG Data    
Resting heart rate (beats/minute) 67.3 (12.7) 61.8 (15.0) 0.05 
PR interval (ms) 150.9 (28.1) 142.9 (22.8) 0.1 
QRS duration (ms) 90.4 (18.2) 106.1 (18.4) <0.001 
Romhilt-Estes Score u2.9 (3.1) 5.5 (2.5) <0.001 
    
Echocardiographic Data    
Maximal LV wall thickness (mm) 11.2 (2.7) 15.0 (4.5) <0.001 
Left atrial size (mm) 36.5 (4.9) 40.6 (7.5) 0.002 
LV end diastolic diameter (mm) 46.0 (4.0) 50.1 (5.6) <0.001 
LV end systolic diameter (mm) 28.4 (3.6) 30.4 (5.6) 0.04 
Fractional shortening (%) 38.4 (6.0) 39.5 (6.7) 0.3 
LV mass index (g/cm2) 99.5 (25.3) 147.1 (48.9) <0.001 
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Table 4.4: Exercise Data Stratified By Gender 
 
 
  
 Females (n = 50) Males (n = 53) Significance 
Peak exercise oxygen consumption (%) 90.5 (26.0) 74.4 (20.8) 0.001 
Work (%) 83.4 (23.8) 63.8 (27.3) <0.001 
Anaerobic threshold (%) 44.2 (9.2) 40.3 (9.0) 0.04 
Heart rate at peak exercise (%) 82.2 (12.6) 75.9 (15.2) 0.02 
Oxygen pulse (%) 110.2 (25.9) 99.8 (22.7) 0.04 
Respiratory quotient 1.0 (0.1) 1.0 (0.1) 0.8 
Δ blood pressure at peak exercise (mmHg) 45.7 (15.6) 57.2 (23.0) 0.004 
Exercise time (minutes:seconds) 07:42 (01:24) 08:01 (02:37) 0.5 
 
 
 
Table 4.4 legend: % = percent of predicted maximum 
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Figure 4.1: Correlation between percentage predicted VO2 max and MSSI score 
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Males had a larger increase in systolic blood pressure during exercise compared to 
females (mean difference = 12.0mmHg, 95% CI = 4.2, 19.7; p = 0.003).  
 
Clinical correlates of pVO2  
There was no relation between pVO2 and a history of chest pain, palpitations or 
syncope. Patients with dyspnoea (NYHA class ≥ II) had a lower pVO2 compared to those 
without (mean difference = 16.4%, 95% CI = 5.6, 27.2; p = 0.003). There was a negative 
correlation between percentage predicted VO2 max and MSSI score (Figure 4.1; r = -
0.5, p < 0.001). There was no correlation between percentage predicted VO2 max and 
the degree of proteinuria (quantified through 24 hour urine collection) or GFR 
(measured using EDTA nuclear medicine techniques). 
 
There was a negative correlation between percentage predicted VO2 max and the QRS 
duration on ECG and the RE score (r = - 0.3 and r = - 0.3; p = 0.006 and p = 0.001 
respectively).  There were significant correlations between percentage predicted VO2 
max and maximal LV wall thickness, left atrial size and LV mass index (r = - 0.2, - 0.3, -
0.2; p = 0.04, 0.007, 0.02 respectively). 
 
To identify the clinical predictors of percentage predicted pVO2, a stepwise regression 
analysis model was used. Co-variates entered into the model were those that were 
identified as being significantly associated with percentage predicted VO2 max; namely: 
gender, NYHA class ≥ II, MSSI score, QRS duration, RE score, maximal LV wall thickness, 
LA size and LV mass index. Using this model the only independent clinical predictor of 
percentage predicted VO2 max was MSSI score (β = - 1.0, 95% CI = - 0.6, -1,4; p < 0.001). 
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Discussion 
This study shows that the majority of men and a substantial minority of women with 
AFD have objective evidence for exercise limitation. The degree of impairment 
correlates with overall disease severity.  
 
There are many potential mechanisms of exercise limitation in patients with AFD. 
Glycosphingolipid accumulation in cardiomyocytes and myocardial fibrosis are 
common in adults with AFD115, 116. By contributing to abnormal myocardial contractility 
and diastolic dysfunction, these abnormalities would be expected to impair stroke 
volume response to exercise and result in elevated left atrial pressure, thereby leading 
to pulmonary congestion and exertional dyspnea. In this study, many patients had 
diminished heart rate responses which contributed to a reduced cardiac output at peak 
exercise. The mechanism of this chronotropic incompetence is unknown, but it 
probably reflects the effect of Gb3 accumulation in the sinoatrial node and specialized 
conduction system of the heart 117 as well as impaired autonomic function 118. Valvular 
disease is also common in patients with AFD, and could theoretically contribute to 
exercise limitation if severe 61.   
 
In this study a number of exercise, ECG and echocardiographic parameters were 
significantly worse in males compared to females. This would be consistent with more 
severe disease manifestations in hemizygous males compared to heterozygous 
females. There was however no significant difference in cardiac symptoms between 
males and females which is consistent with previous data119. 
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Mild airflow obstruction is common in patients with AFD 120. It is similar to the fixed 
obstruction that is seen in COPD with infiltration of inflammatory cells, smooth muscle 
hyperplasia, uncoupling of smooth muscle from the adventitia, bronchial wall 
hypertrophy and fibrosis being potential mechanisms 120. This was not quantified in this 
study but may have impacted on pVO2.  
 
The percentage of predicted VO2 max correlated significantly with MSSI score, ECG 
parameters (RE score and QRS duration) and echocardiographic parameters (maximal 
LV wall thickness, left atrial size and LVMI). However, the only independent predictor 
of pVO2 was found to be MSSI score, This is perhaps not surprising given that both MSSI 
and pVO2 take account of multiple organ systems affected by AFD, but suggests that 
cardiopulmonary exercise testing may be a useful method for assessing disease severity 
and perhaps the response to enzyme replacement therapy. 
 
In conclusion, objective impairment of exercise capacity is common in patients with 
AFD and may be a useful marker of disease severity which deserves further 
investigation.    
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Chapter 5 
 
Coronary microvascular 
function, its relation to 
symptoms and response to 
enzyme replacement therapy 
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Abstract 
Background   
In chapter 3, I described how patients with AFD develop progressive systolic 
dysfunction.  AFD cardiomyopathy is also associated with myocardial fibrosis.  These 
phenomena could be secondary to coronary microvascular dysfunction.  Aim of this 
study was to measure coronary flow reserve (CFR), an index of microvascular function, 
in AFD at baseline and after enzyme replacement therapy (ERT). 
 
Methods and results  
Myocardial blood flow (MBF) at rest and during hyperaemia (adenosine 140 μg/kg/min) 
was measured in 10 male, non-smoking patients (53.8±10.9 years, cholesterol 5.5±1.3 
mmol/l) and 24 age matched male, non-smoking controls (52.0±7.6 years, cholesterol 
4.5±0.6 mmol/l) using positron emission tomography (PET). Resting and hyperaemic 
MBF and CFR (hyperaemic/resting MBF) were reduced in patients compared to controls 
(0.99±0.17 vs. 1.17±0.25 ml/g/min, p<0.05; 1.37±0.32 vs. 3.44±0.78 ml/g/min, 
p<0.0001 and 1.410.39 vs. 3.030.85, p<0.0001, respectively). This coronary 
microvascular dysfunction was independent of cholesterol levels. A repeat PET scan 
was carried out in 5 patients after 10.1±2.3 months of ERT; resting and hyperaemic 
MBF and CFR were unchanged after ERT (0.9930.16 vs. 0.9910.16 ml/g/min, p=ns; 
1.560.29 vs. 1.710.3 ml/g/min, p=ns and 1.60.37 vs. 1.740.28, p=ns respectively).  
 
Conclusions 
The results of the present study demonstrate that patients with AFD have markedly 
abnormal coronary microvascular function. Our preliminary data suggest that ERT has 
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no effect on coronary microvascular dysfunction. Further work is necessary to 
determine whether treatment at an earlier stage in the course of the disease may 
improve coronary microvascular function in AFD patients. 
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Aims 
Patients with AFD complain of angina despite angiographically normal coronary 
arteries. I have previously described a progressive deterioration in left ventricular 
systolic function and a previous study from this group has demonstrated myocardial 
scarring in patients with AFD cardiomyopathy63, 121. The aim of this study was to see if 
these clinical abnormalities may be caused by coronary microvascular dysfunction.  
 
The aims of this study were to measure coronary flow reserve (CFR), an index of 
coronary microvascular function, in a consecutive cohort of patients with AFD using 
positron emission tomography (PET), and to determine the effect of ERT on 
microvascular abnormalities. 
 
Methods 
Patient and Controls 
Ten non-smoking male patients with AFD (53.8 ± 10.9 years, range 43-82, cholesterol 
5.5±1.3 mmol/l) referred to the Heart Hospital, London, UK were studied. The diagnosis 
of AFD was based on the identification of an -Gal gene mutation and a low plasma -
Gal (mean 0.45  0.35 nmol/hr/ml, range 0.04-0.99 nmol/hr/ml). Nine patients were 
identified through screening of patients presenting with unexplained left ventricular 
hypertrophy (LVH). One patient was referred with an established diagnosis of AFD (# 
6), and 1 was identified through family screening; (# 10). At the time of diagnosis, none 
of these patients were receiving ERT.  
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All patients had ECG and 2-D/Doppler echocardiography performed using the 
previously described methods in chapter 2.  Nine patients had symptoms and/or signs 
suggestive of myocardial ischaemia and underwent coronary angiography to exclude 
coronary artery disease. 
 
Twenty four healthy non-smoking age matched males (52.08 years, cholesterol 
4.5±0.6 mmol/l) with normal electrocardiograms (ECG), and no evidence of cardiac 
disease served as controls for the MBF and CFR data.  
 
Enzyme Replacement Therapy 
Five patients (Table 5.1) received FabrazymeTM (Genzyme Corporation, Cambridge MA, 
USA) at a dose of 1 or 2 mg/kg every two weeks as part of a separate randomised study. 
Follow up PET scans were obtained 17.11.9 months after the baseline scan while 
patients were on treatment (mean 10.1±2.3 months on ERT). Plasma 
globotriaosylceramide (neutral glycosphingolipid) levels were measured using tandem 
mass spectrometry pre- and post ERT122. 
 
The study was approved by the Local Research Ethics Committees and all participants 
gave written informed consent. Radiation exposure was approved by the UK 
Administration of Radioactive Substances Advisory Committee (ARSAC). 
 
Positron Emission Tomography (PET) 
All patients and controls underwent PET scanning to measure MBF at rest and during 
adenosine-induced hyperaemia (140 μg/kg/min i.v.). Scanning was performed with an 
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ECAT 931-08/12 15-slice tomograph with a 10.5-cm axial field of view (CTI/Siemens, 
Knoxville, TN). Resting and hyperemic MBF were measured using oxygen-15 labeled 
water (H215O) as previously reported123. Arterial blood pressure was recorded by 
automatic cuff sphygmomanometer at one-minute intervals and the ECG was 
monitored continuously throughout the procedure.  
 
PET Data Analysis 
All emission and transmission data were reconstructed using a Hanning filter with a 
cut-off frequency of 0.5 units of the reciprocal of the sampling interval of the projection 
data resulting in an image resolution of 8.4x8.3x6.6 mm full width at half maximum at 
the centre of the field of view. Myocardial and blood pool images were then generated 
directly from the dynamic H215O study as previously reported124.  Regions of interest 
were drawn within the left atrium and ventricular myocardium on consecutive image 
planes. These were projected onto the dynamic H215O images to generate blood and 
tissue time activity curves. Arterial and tissue activity curves were fitted to a single tis-
sue compartment tracer kinetic model to give values of MBF (ml/g/min)124. Coronary 
resistance (mmHg/ml/min/g) was calculated as the ratio of mean arterial pressure to 
MBF and CFR as the ratio of hyperaemic MBF to resting MBF.  
 
Statistical Analysis 
Comparisons between continuous variables were performed using the paired Student 
t-test (SPSS v19.0; SPSS, Inc., Chicago, Illinois, USA). Linear regression was performed 
to assess the relationship between cholesterol levels, LVM index, MBF and CFR. Data 
are reported as mean ± SD values. A p<0.05 was considered significant.  
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Results 
Patient Characteristics 
The clinical characteristics of the patients are shown in Table 5.1. Six (60%) patients 
complained of exertional chest pain. None of the nine patients had angiographically 
significant coronary artery disease. Three patients had rate responsive dual chamber 
permanent pacemakers: one for left ventricular outflow tract gradient reduction and 
two for heart block. None of the patients had a PR interval less than 120ms. Two 
patients had non-sustained ventricular tachycardia on Holter (# 2 and 3), and 2 were in 
atrial fibrillation (# 5 and 11). Seven years prior to the diagnosis of AFD, patient #1 had 
undergone an assessment of coronary sinus pH during dipyridamole infusion125. The 
peak change in coronary sinus pH during hyperaemia was -0.086 units, indicating 
severe myocardial ischaemia. 
 
Serum cholesterol was higher in the patients compared to controls (mean difference 
0.97 mmol/l, 95% CI = 0.3-1.6, p = 0.006). Patients also had higher HDL cholesterol 
levels compared to controls (1.7±0.5 mmol/l vs. 1.1±0.4 mmol/l, respectively, p = 
0.002). There were no differences in LDL cholesterol (3.1±0.8 mmol/l vs. 3.7±1.3 
mmol/l, patients vs. controls respectively, p = 0.2) and triglyceride levels (1.4±0.7 
mmol/l vs. 1.8±1.6 mmol/l, patients vs. controls respectively, p = 0.5). 
 
Two patients had acroparaesthesiae, 1 had hypohidrosis and 1 had renal dysfunction 
(creatinine clearance 52 ml/min). None of the patients were hypertensive and one was 
a type 2 diabetic. No angiokeratomata were noted in any of the patients. All patients 
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had a maximal left ventricular wall thickness  13mm (17  4.0 mm, range 14-26 mm). 
Nine patients had concentric left ventricular hypertrophy (LVH) and 1 had asymmetric 
septal hypertrophy.  At the time of study no patient had left ventricular outflow tract 
obstruction; the mean left ventricular end-systolic, end-diastolic and left atrial 
diameters were 330.9, 5208 and 47 11 mm respectively. The mean LVM index was 
23481.3g/m2 (range 141- 407 g/m2).  
 
Myocardial Blood Flow and Coronary Flow Reserve  
Heart rate and mean arterial blood pressure were similar in controls and AFD patients 
at rest and during adenosine infusion. The rate pressure product (RPP= systolic blood 
pressure x heart rate) was similar in the controls and patients during all study 
conditions. 
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Table 5.1: Patient characteristics. 
 
 
Patient 
Age at 
study 
(years) 
Chest pain NYHA Class Syncope Palpitations 
Max. 
LVWT 
(mm) 
FS 
(%) 
 
LVM 
index 
(g/m2) 
 
CFR 
1 46 + II + + 25 40 263 1.58 
2* 58 - I + + 26 26 407 2.60 
3* 81 - III - + 18 23 228 2.31 
4 49 + II - - 17 35 192 2.09 
6* 55 + II - + 15 36 222 2.24 
7* 49 + II - + 16 39 180 2.74 
8 45 + I - + 20 51 248 1.27 
9* 54 - I - - 24 42 314 2.27 
10 43 - I - - 15 33 93 1.28 
12 58 + II + + 20 27 407 1.83 
 
 
Table 5.1 legend: NYHA=New York Heart Association, Max LVWT = maximal left ventricular wall thickness, FS = fractional shortening, %=percentage, CFR = coronary 
flow reserve, * = 5 patients with follow-up PET scans following Enzyme Replacement Therapy.  
94 
 
Resting and hyperaemic MBF and CFR were significantly reduced in AFD patients 
compared to controls (0.990.17 vs. 1.170.25 ml/g/min, p<0.05, 1.370.32 vs. 
3.440.78 ml/g/min, p<0.0001 and 1.410.39 vs. 3.030.85, p<0.0001), respectively 
(Figure 5.1 and Table 5.1). This reduction in coronary microvascular function was 
independent of cholesterol and HDL cholestero1 levels. Resting coronary resistance 
was comparable in patients and controls (82.2±27.8 vs. 89.3±31.2 mmHg/ml/min/g 
p=ns respectively). The minimal resistance during hyperaemia was higher in AFD 
patients compared to controls (65.1±16.9 vs. 26.5±6.0 mmHg/ml/min/g p<0.0001). No 
correlation was found between LVM index and resting or hyperaemic MBF or CFR.  
 
Response to ERT 
In those patients that underwent a repeat PET scan there was a decrease in plasma 
globotriaosylceramide with ERT (mean change=5.3 μg/ml, 95% CI = 0.5, 10.1, p=0.04). 
Resting and hyperaemic MBF and CFR, before and after 10.1±2.3 months of ERT were 
similar (0.99±0.16 vs. 0.99±0.16 ml/g/min, p=ns, 1.56±0.29 vs. 1.71±0.3 ml/g/min, p=ns 
and 1.6±0.37 vs. 1.74±0.28, p=ns respectively, Figure 5.2). Resting coronary resistance 
was similar pre- and post- ERT (83.9±18.9 vs. 90.2±26.5 mmHg/ml/min/g, p=ns) 
respectively. 
 
The minimal resistance during hyperaemia was unchanged following ERT (56.9±14.7 vs. 
52.8±18.7 mmHg/ml/min/g, p=ns). There was no change in LVM index (mean 
change=0.4±37.8 g/m2, ranging from -66.3 to +26.4, p=ns).  
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Figure 5.1: Myocardial Blood Flow at Rest and During Adenosine-Induced Hyperaemia in Patients with Anderson-Fabry Disease and Controls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 legend: MBF = Myocardial blood flow, Base = MBF at rest, ADO = MBF during adenosine. 
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Figure 5.2: Myocardial Blood Flow at Rest and During Adenosine-Induced Hyperaemia Pre- and Post Enzyme Replacement Therapy (FabrazymeTM). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 legend: MBF = Myocardial blood flow, Base = MBF at rest, ADO = MBF during adenosine. 
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There were no changes in the left ventricular cavity dimensions (mean change in end 
systolic cavity dimension=0.1±0.3mm, p=ns; mean change in end diastolic cavity 
dimension=0.1±0.2mm, p=ns). 
 
There was a trend to a reduction in fractional shortening (mean fractional shortening 
pre-ERT=34.8±6.7%, mean post-ERT=31.4±6.3%, p=0.08). There was no change in the 
maximal left ventricular wall thickness (mean change=0.02±0.3mm, p=ns). 
 
Discussion 
This study shows that patients with AFD have a substantial reduction in hyperaemic 
MBF and CFR compared to normal controls. The significance of these findings for 
individual patients remains to be determined, but the severity of the microvascular 
dysfunction suggests that these abnormalities may have a substantial influence on the 
natural history of AFD.  
 
Mechanisms of Microvascular Dysfunction 
Symptoms and signs suggestive of myocardial ischaemia in the absence of coronary 
disease are frequent in patients with cardiomyopathies and in individuals with left 
ventricular hypertrophy secondary to pressure overload. Reductions in CFR similar to 
those seen in this study have been demonstrated in all these conditions, although 
different mechanisms are involved. In patients with hypertrophic cardiomyopathy, 
remodelling of the intramural arterioles is important126,127, whereas in aortic stenosis, 
increased perivascular fibrosis and intramyocardial pressure and reduced diastolic 
filling are the dominant mechanisms for microvascular dysfunction128, 129. 
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In AFD, a number of mechanisms may contribute to microvascular dysfunction. AFD 
cardiomyopathy is characterised by GB3 deposition in myocytes, conduction tissue, 
vascular endothelium and valvular tissue. This is accompanied by secondary changes 
such as myocyte hypertrophy and fibrosis130 which cause raised coronary vascular 
resistance and increased myocardial oxygen demand. Although endothelial GB3 
deposits may lead to microvascular dysfunction, a recent publication has shown that 
patients with AFD have enhanced nitric oxide independent endothelial function 
measured using forearm venous plethysmography131. It remains to be seen whether 
similar abnormalities are seen in the coronary microvasculature.  
 
Response to ERT 
In this study there was a significant reduction in the plasma levels of 
globotriaosylceramide with ERT, but no improvements in coronary microvascular 
function or LVM were seen. However, interpretation of this observation is limited by 
the small size of the cohort and by the fact that the cohort was considerably older, and 
had more severe cardiac disease compared to patients included in previous trials of 
ERT73, 75, 132. Along with an improvement in AFD symptoms these trials have 
demonstrated a reduction in LVM and an improvement in systolic function with ERT. In 
order to understand the impact of ERT on coronary microvascular function a larger 
study conducted over a longer period of time is required. 
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Conclusion 
This study shows that microvascular dysfunction is important in the pathophysiology of 
AFD cardiomyopathy. Further studies are required to assess the impact of enzyme 
replacement therapy on microvascular function. 
 
 
 
  
100 
 
 
 
Chapter 6 
 
Extracellular matrix turnover in 
Anderson-Fabry disease 
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Abstract 
Background 
Patients with AFD develop progressive left ventricular (LV) remodelling and heart 
failure. We hypothesized that altered extracellular matrix turnover (ECM) contributes 
to the pathophysiology of cardiac disease in AFD. 
 
Methods and results 
Twenty-nine (44.1±11.7 years, 15 male) consecutive patients with AFD and 21 normal 
controls (39.7±11.3 years, 10 male) had serum analysed for matrix metalloproteinase-
9 (MMP-9), and tissue inhibitor of matrix metalloproteinase 1 and 2 (TIMP-1, TIMP-2). 
All patients underwent clinical assessment, echocardiography and Mainz Severity Score 
Index measurement (MSSI); a validated severity score in AFD. 
 
MMP-9 levels were significantly higher in patients than controls (1003.8±337.8ng/ml 
vs. 576.7±276.3ng/ml respectively, p < 0.001). There were no differences in TIMP levels 
between patients and controls. There was a positive correlation between MMP-9 levels 
and MSSI (r = 0.5, p=0.01). There was a negative correlation between MMP-9 and 
fractional shortening (FS, r = -0.5, p=0.01). There was no correlation between LV mass 
or maximal LV wall thickness and MMP-9 levels. These relations were independent of 
age and gender using stepwise linear regression analysis. 
 
Conclusions  
Patients with AFD have abnormal ECM turnover compared to normal controls.  The 
correlation between MMP-9 levels and FS suggests that altered ECM turnover is 
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important in cardiac remodelling. The association between MMP-9 and overall disease 
severity suggests that circulating levels of matrix metalloproteinases may provide a 
useful marker for assessing the response of patients with AFD to enzyme replacement 
treatment. 
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Aim 
Previous chapters have described progressive left ventricular dysfunction, significant 
arrhythmia and significant exercise limitation.  
 
Matrix metalloproteinases (MMPs) and their endogenous inhibitors, tissue inhibitors 
of metalloproteinases (TIMPs) are the key mediators of extracellular matrix (ECM) 
turnover, the balance between constitutive enzyme activity and inhibitor activity 
ultimately determining ECM composition for a variety of elements. While tissue 
composition is the key a variety of studies have suggested that the measurement of 
circulating MMPs and TIMPs are associated and provide a non-invasive assessment of 
ECM turnover133-135. For example circulating levels of TIMP-1 appear to correlate with 
the severity of structural left ventricular hypertrophy and related diastolic filling 
abnormalities in hypertensive heart disease136, 137. 
 
The aim of this study was to assess if patients with AFD have abnormal collagen 
turnover as compared to age matched normal healthy cohort and to assess its 
relationship to overall disease severity.   
 
Methods 
The study cohort comprised 29 consecutive patients (mean age 44.1 ± 11.7 years, 15 
(60.0%) male and 14 (40.4%) female) with a genetically confirmed diagnosis of AFD and 
21 age and gender matched healthy normal controls (mean age 39.7 ± 11.3 years, 10 
(47.6%) male and 11 (52.4%) female). The latter were asymptomatic and had no clinical 
evidence of vascular, neoplastic, metabolic or inflammatory disease (assessed by 
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history, examination and routine laboratory analysis). All controls were normotensive 
(supine blood pressure <140/90 mmHg), and had a normal resting ECG. All were free 
of drug therapy. 
 
The study was approved by the local research ethics committee and informed, written 
consent was obtained from all patients and controls. 
  
Clinical Assessment 
All patients underwent a complete clinical assessment with clinical history, 
examination, a standard 12 – lead electrocardiogram (ECG) and echocardiography as 
described previously in chapter 2.  
 
Mainz Severity Score Index (MSSI) 
In brief, the MSSI scoring system comprises four components: general, neurological, 
cardiovascular and renal (chapter 4, Table 4.1)106. Each component consists of a group 
of signs and symptoms associated with AFD, weighted according to their contribution 
to morbidity. For each sign and symptom, a score is assigned and summed to produce 
a total score for that component (chapter 4, Table 4.1). These individual component 
scores are then totalled to give the final MSSI score. 
 
MMP-9, TIMP-1 and TIMP-2 Evaluation 
Circulating concentrations of serum MMP-9, TIMP-1 and TIMP-2 were measured by an 
in house enzyme linked immunosorbent assay as described previously135. In brief, 
serum was stored in aliquots at -20ºC and batch analysed for MMP and TIMP. 
105 
 
Monoclonal primary and biotinylated secondary antihuman antibody for total MMP-9, 
TIMP-1 and TIMP-2 were tested against respective recombinant human MMP and TIMP 
(MAB911, BAF911, 911-MP; MAB970, BAF970, 970-TM; MAB9711, BAF971, 971-TM; 
R&D Systems Europe Ltd, Abingdon, UK) and against pooled human plasma to 
determine the optimal concentration of primary (2 μg/mL, 4 μg/mL and 2 μg/mL 
respectively) and secondary antibody (0.1 μg/mL, 0.1 μg/mL and 0.2 μg/mL 
respectively) sample dilution (1/100) and standard. The mean intra-assay coefficient of 
variation (CV) and mean inter-assay CV for the assays were <5% and <10% respectively.  
 
Statistics 
Statistical analysis was performed using SPSS v19.0. The χ2 test was used to compare 
non-continuous variables. Normally distributed variables were compared using the 2-
tailed independent sample Student t-test and non-normally distributed variables were 
compared using the Man Whitney U test. Correlations for normally distributed 
variables were expressed as a Pearson’s correlation coefficient and non-normally 
distributed variables as a Spearman’s rho coefficient. All values were expressed as 
means (standard deviation) for normally distributed variables and median 
(interquartile range) for non-normally distributed variables.   
 
Stepwise linear regression was used to assess the relationship between circulating 
MMP and TIMP levels and markers of disease severity were adjusted for covariates. As 
females develop signs and symptoms of the disease at older ages, gender was entered 
into the regression model; age was entered into the regression model as there is a 
progressive accumulation of glycosphingolipid with advancing age.   
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Table 6.1: Baseline Characteristics in Males and Females 
 Total Female (14) Male (15) 
p-
value 
*TIMP-2 (ng/ml) 210 (190-250) 198.5 (188.8-265) 210 (190-240) 0.9 
TIMP-1 (ng/ml) 1029.7 (299.3) 996.8 (276.2) 1060.3 (326.0) 0.6 
MMP-9 (ng/ml) 1003.8 (337.8) 887.1 (307.9) 1112.7 (337.5) 0.07 
Age (years) 44.1 (11.7) 45.7 (13.5) 42.5 (10.0) 0.5 
MSSITOTAL 26.9 (14.7) 17.1 (10.4) 36.0 (12.1) <0.001 
MSSIGENERAL 6.5 (4.2) 3.6 (2.1) 9.0 (4.1) <0.001 
MSSINEUROLOGICAL 5.6 (4.6) 4.2 (3.4) 6.9 (5.2) 0.1 
MSSICARDIAC 8.7 (5.8) 5.2 (5.5) 11.9 (4.0) 0.001 
MSSIRENAL 5.5 (5.2) 3.1 (3.6) 7.7 (5.5) 0.01 
PR interval (ms) 147.3 (30.1) 156.5 (35.4) 138.7 (22.0) 0.1 
QRS Duration (ms) 93.2 (14.3) 82.9 (7.9) 102.9 (12.0) <0.001 
Max LV Wall Thickness (mm) 13.4 (4.3) 10.9 (1.8) 15.8 (4.5) 0.001 
*RWT 0.5 (0.4-0.6) 0.4 (0.4-0.5) 0.6 (0.5-0.6) 0.01 
LVed (mm) 47.4 (4.0) 45.9 (2.2) 48.7 (4.8) 0.06 
LVes (mm) 29.0 (3.9) 27.4 (2.7) 30.4 (4.3) 0.04 
FS (%) 38.7 (7.5) 40.1 (5.3) 37.3 (9.1) 0.3 
*LV Mass Index (g/cm2) 96.8 (91-145) 92.0 (82.6-95.8) 132.4 (101-183) <0.001 
 
Table 6.1 legend: TIMP = tissue inhibitor of matrix metalloproteinases; MMP = matrix 
metalloproteinase; MSSI = Mainz Severity Score Index; Max LV = maximal left ventricular; RWT 
= relative wall thickness; LVed = left ventricular end diastolic cavity dimension; LVes = left 
ventricular end systolic cavity dimension; FS = fractional shortening; * = non-normally 
distributed variables comparison made using Man Whitney U test, expressed as median 
(interquartile range), normally distributed variables expressed as mean (standard deviation). 
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Other covariates were entered into the model if there was a relationship between the 
covariate and MMP or TIMP with a p-value of < 0.05 on univariate analysis. Statistical 
significance was defined as p < 0.05.  
 
Results 
The clinical characteristics of the patients are shown in Table 6.1. MMP-9 levels were 
elevated in patients with AFD by a mean of 427.1 ng/ml (95% CI = 252.1, 602.2 ng/ml, 
p < 0.001, Figure 6.1). There were no differences between patients and controls in 
TIMP-1 and TIMP-2 levels. 
 
Disease Severity and MMP-9 
Table 6.1 describes each of the MSSI component scores stratified by gender. The mean 
MSSITOTAL score was higher in men compared to women (19.1, 95% CI = 10.7 to 27.5, 
Table 6.1).  
 
Similarly, the mean MSSIGENERAL, MSSICARDIAC and MSSIRENAL but not 
MSSINEUROLOGICAL scores were higher in men compared to women (5.4, 95% CI = 2.7 
to 7.6; 6.7, 95% CI = 2.9 to 10.4; 4.6, 95% CI = 1.0 – 8.2; 2.7, 95% CI = -0.6 to 6.1 
respectively, table 6.1). There was a positive correlation between MMP-9 levels and 
MSSITOTAL, MSSIGENERAL and MSSINEUROLOGICAL, scores (r = 0.5, p = 0.01, Figure 
6.2; r = 0.4, p = 0.03; r = 0.4, p = 0.047 respectively), but not with MSSICARDIAC or 
MSSIRENAL scores. 
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Figure 6.1: Difference in Matrix Metalloproteinase – 9 between Patients and Controls 
 
Figure 6.1 legend: Box and whiskers plot for controls and patients. Boxes represent median ± interquartile range (580ng/ml ± 920 ng/ml for controls and 1100 ng/ml ± 
1220 ng/ml for patients, p< 0.001). 
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Figure 6.2: Correlation between Metalloproteinase – 9 and Disease Severity 
 
Figure 6.2 legend: Disease severity assessed as Mainz Severity Score Index (MSSITOTAL). 
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Figure 6.3: Correlation between Metalloproteinase – 9 and Fractional Shortening 
 
Figure 6.3 legend: Fractional shortening assessed on echocardiography and expressed as a percentage. 
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Cardiovascular Evaluation 
Four of the 29 (13.8%) patients complained of angina, 5/29 (17.2%) were in NYHA class 
2 or greater, 8/29 (27.6%) complained of palpitations and none had experienced pre-
syncope/syncope. There were no gender differences in the frequency of cardiac 
symptoms. 
 
All patients were in sinus rhythm. The mean PR interval was 147.3 ± 30.1 ms (100 – 223 
ms) with a mean QRS duration of 93.2 ± 14.3 ms (72 – 132 ms). Men had a higher QRS 
duration when compared to women (mean difference = 19.9 ms, 95% CI = 12.1ms to 
27.8ms, p < 0.001, Table 6.1). 
 
Seventeen (58.6%, 12 males and 5 females) patients had evidence of cardiac 
remodelling. Eight (27.6%, seven males) had evidence of concentric hypertrophy, 9 
(31.0%, 5 males) had concentric remodelling and 12 (41.4%, 3 males) had normal LV 
geometry.   
 
The mean maximum LV wall thickness was 13.4 ± 4.3 mm (8 - 26mm), with a mean RWT 
of 0.5 ± 0.1 (0.3 - 1.0) and a mean LVMI of 121.3 ± 48.4 gm/m2. Men had higher maximal 
LV wall thickness (mean of 4.9mm, 95% CI = 2.3mm to 7.6mm); higher RWT (mean of 
0.1, 95% CI = 0.03 to 0.2); and higher LVMI (mean 56.1 gm/m2, 95% CI = 25.8 to 86.4 
gm/m2) when compared to women (Table 6.1). Men had a higher LVes, a trend to 
higher LVed and no difference in the FS when compared to women (Table 6.1).   
 
There was a negative correlation between MMP-9 levels and FS (r = -0.4, p = 0.02, Figure 
6.3). There was a trend to a positive correlation between MMP-9 levels and QRS 
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duration (r = 0.4, p = 0.047) and RWT (r = 0.4, p = 0.06). MMP-9 levels did not correlate 
with LVMI or left ventricular cavity dimensions.  
 
Stepwise linear regression demonstrated a relation between MMP-9 levels and MSSI 
score and FS that was independent of age and gender (β = 11.0, 95% CI = 3.9 to 18.7, p 
= 0.004; β = -20.2, 95% CI = -6.4 to -33.9, p = 0.006).   
 
Discussion 
This study demonstrates that patients with AFD have elevated levels of circulating 
MMP-9 when compared to normal controls. MMP-9 levels correlated with clinical 
markers of disease severity, suggesting that abnormal ECM turnover plays an important 
role in the pathogenesis of AFD.  
 
MMP in Heart Disease 
The ECM is composed of a wide range of elements including collagen, elastin, 
specialised proteins (fibrillin and fibronectin) and proteoglycans. It has an important 
role in the maintenance of the structural integrity and function of organs and influences 
both intracellular signalling and cell-to-cell interactions. Although the ECM is 
ubiquitous, its composition can vary from organ to organ138. 
There are more than twenty different MMP’s, each acting on a number of ECM 
substrates138, 139. MMP-9, also known as gelatinase, is a 92-kD protein secreted by 
myocytes, fibroblasts, smooth muscle cells and neutrophils; its function is to degrade a 
number of interstitial proteins including basement membrane components such as 
laminin and fibronectin138. 
113 
 
 
Increased MMP expression occurs in several disease states including tumour 
angiogenesis and metastasis, rheumatoid arthritis and vascular disease140, 141. It has 
been shown recently that circulating levels of MMP-9 predict disease severity and 
prognosis in stable and unstable coronary artery disease, peripheral arterial disease 
and hypertension134, 142, 143. Myocardial and blood levels of MMP-9 are elevated in 
patients with ischaemic and non-ischaemic left ventricular dilatation144, 145. In the low 
risk population studied in The Framingham Heart Study blood levels of MMP-9 were 
associated with increased left ventricular cavity dimensions and mass index146. TIMP-1 
activity is increased in hypertension and diabetes and is associated with myocardial 
fibrosis and diastolic dysfunction 137; TIMP-2 has been linked with angiogenesis147.  
 
Significance of ECM Turnover in AFD 
Although the genetic and biochemical basis of AFD is well described, the 
pathophysiology of cardiac disease in AFD is inadequately understood. Histologically, 
AFD cardiomyopathy is characterised by myocyte hypertrophy and vacuolation97. 
However, substrate accumulation accounts for only 1% of the increased LV mass seen 
in AFD cardiomyopathy62.  
 
The findings in this study support recent data from cardiac magnetic resonance imaging 
suggesting that myocardial fibrosis may be a key determinant of cardiac function in 
AFD63. The main impact of elevated MMP-9 levels is to increase collagen type I / III 
ratio139. Collagen type I is not a major substrate for MMP-9, and hence raised levels of 
MMP-9 may reflect the breakdown of components other than collagen type I139. 
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Although TIMP-1 directly inhibits the degradation of collagen type I in the ECM, there 
were no differences in circulating levels between patients and controls. It is possible 
that elevated MMP-9 levels may directly increase collagen gene expression in the 
absence of elevated TIMP-1 levels148. Moreover, it is likely that the balance between 
TIMP and MMP activities is more important than abnormalities in either factor in 
isolation. 
 
Monitoring of Disease Activity 
The recent introduction of enzyme replacement therapy for the treatment of AFD 
represents a major advance in the treatment of lysosomal diseases75. A new challenge 
for clinicians treating such diseases is the monitoring of response to therapy. In some 
diseases  there are highly sensitive circulating markers (e.g. chitotriosidase in Gaucher 
disease) that can be used; in AFD plasma and urine levels of Gb3 have been used, but 
recent evidence suggests that this may not be the most appropriate marker for 
monitoring response to treatment122. The association between MMP-9 and overall 
disease severity suggest that ECM turnover may be a useful alternative surrogate for 
the response to enzyme replacement treatment 
 
Conclusion 
Patients with AFD have abnormal ECM turnover; the relation between MMP-9 levels 
and disease severity suggests that altered ECM remodelling is central to the 
pathogenesis of AFD related complications.  
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Chapter 7 
 
Summary of findings and current 
literature 
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Summary of findings and current literature 
The aim of this thesis was to perform the first detailed characterisation of cardiac 
manifestations of AFD and to explore their relation to outcomes. Many of the findings 
were completely novel and have been confirmed in subsequent studies from our own 
group and other investigators. 
 
Arrhythmia 
In chapter two, I demonstrated that there is an increase in prevalence of both 
supraventricular and ventricular arrhythmia with age and that approximately 5% of 
patients required a permanent pacemaker at follow up.  These findings suggested that 
cardiac arrhythmia may be a significant contributor to long-term morbidity and 
mortality in AFD.  The high contribution of arrhythmia to symptoms has been confirmed 
in subsequent studies reporting palpitations or documented arrhythmia in 19.3% of the 
population in the international Fabry outcome survey not on ERT and 34.5% of the 
population on ERT119. Older patients with AFD are more likely to develop bundle branch 
block and atrioventricular conduction/sinus node disease149 and in the FOS registry 3% 
of these patients required antibradycardia pacing119.  Additionally most males have a 
resting bradycardia and chronotropic incompetence (also described in chapter 4)150 and 
male children have reduced heart rate variability151.   
 
Work from our own cohort has shown that PR interval and QRS duration increase with 
age and are independent predictors of future anti-bradycardia pacing (hazard ratio HR 
1.03, 95% CI 1.004–1.060, p = 0.02; HR 1.05, 95% CI 1.02–1.09, p < 0.001 respectively)152.  
In this study the annual implant rate for any cardiac device (anti-bradycardia or high 
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energy defibrillator device) was 2.1% (95% CI = 1.2-3.1) with a 5 year cumulative 
incidence of 12% (95% CI = 6.1-17.9%)152.  
 
Although the high prevalence of tachyarrhythmia has been documented in chapter 2 
and other studies, its impact on the natural history of the disease is still uncertain.  In 
rare instances it may be the first presentation of AFD cardiomyopathy153.  Sudden 
cardiac death is rare in AFD, however it is likely from published literature that 
bradycardia as well as ventricular tachycardia would contribute95, 154.  Weidemann et al 
followed 40 patients with advanced AFD on ERT and demonstrated a sudden cardiac 
death risk of 15% (6/40, total of 7 deaths in cohort)155. All of these patients had 
documented non-sustained ventricular tachycardia and myocardial fibrosis on cardiac 
MRI scanning155. Further research is needed to identify those at greatest risk and 
institute appropriate preventative therapies for the prevention of sudden cardiac 
death156. 
 
Histological examination of the conduction tissue demonstrates that the greater the 
involvement of the conduction tissue with GB3 deposition the greater the accelerated 
conduction with prolonged refractoriness and the greater the electrical instability76, 157. 
   
With the high prevalence of stroke in patients with AFD it is likely that AF contributes 
to this, but there are no data regarding thromboprophylaxis for patients with AFD 
cardiomyopathy and documented AF44.  The pathophysiology of cerebrovascular 
disease is not completely understood, but is likely to be multifactorial including 
microvascular disease, increased thrombotic potential, arteriopathy and 
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thromboembolic49-51.  Although risk stratification algorithms such as CHA2DS2-VASc 
score have been validated in the general population, it is unlikely that this would be 
applicable to the AFD population as the age of onset of atrial arrhythmia is much 
younger than in the general population91. It would seem intuitive that they should be 
considered for formal anticoagulation, particularly if there are high risk factors such as 
a mutation in the Factor V Leiden gene90. 
 
Left ventricular systolic function 
Chapter 3 described the progressive deterioration in LV systolic function in a small 
cohort of patients with severe AFD cardiomyopathy.  This change occurred without 
change in LV mass index and suggested that systolic function may be a useful marker 
for the assessment of disease progression and response to treatment.  The relationship 
with FS and disease progression is likely to be related to inferior posterior myocardial 
scar that is seen on histology and CMR and is a limitation of the study76, 158. 
 
The most common finding in AFD cardiomyopathy is that of LV hypertrophy and is 
associated with cardiac symptoms119.  The prevalence of LV hypertrophy increases with 
age, occurring earlier in males than in females and inversely associated with renal 
function119.  Early stages of AFD cardiomyopathy are characterised by concentric LV 
remodelling which progresses to LV hypertrophy with time, with asymmetric septal 
hypertrophy seen in 5% of cases119.  Additionally, right ventricular hypertrophy is also 
seen, usually in association with LV hypertrophy159.  Right ventricular hypertrophy is 
seen in equal frequencies in males and females159.  It becomes increasingly recognised 
with advancing age.  The impact of right ventricular hypertrophy on right ventricular 
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function is contradictory in the literature159, 160 and its impact on prognosis remains to 
be determined. 
 
While echocardiography remains the mainstay for diagnosis of LV hypertrophy, there 
have been surprising few studies that have examining the change in systolic function in 
prospective cohorts. Tissue Doppler imaging appears to be a sensitive marker for early 
AFD cardiomyopathy with longitudinal velocities being depressed in the lateral and 
septal aspects of the mitral valve annulus prior to overt LV hypertrophy116.  These tissue 
Doppler indices (in-vivo) correlate with resting and active tension in cardiomyocytes 
(in-vitro) but not with cardiomyocyte area, % storage of GB3 or % fibrosis161.  These 
findings suggest that myofilament degradation and dysfunction contribute to systolic 
impairment161. Importantly, tissue Doppler indices appear to improve with enzyme 
replacement therapy, unless there is advanced AFD cardiomyopathy present74, 162.  A 
recent study has suggested that a binary appearance of the left ventricular endocardial 
border on 2-dimensional echocardiography is a highly sensitive and specific 
discriminator of AFD from hypertrophic cardiomyopathy, however our group have not 
been able to reproduce this finding163, 164. 
 
Exercise limitation 
In chapter 4 I demonstrated that exercise limitation is common in males and in a 
substantial minority of females. The degree of impairment was not only related to 
severity of cardiac involvement, but also to overall disease severity as expressed by the 
MSSI score.  This relationship was not influenced by the degree of proteinuria or GFR.  
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Additionally, males tended to have a degree of chronotropic incompetence which may 
have contributed to their exercise limitation. 
 
Exercise limitation assessed with cardiopulmonary exercise testing has subsequently 
been demonstrated in several studies.   Bierer et al. demonstrate a higher proportion 
of patients with abnormal peak exercise oxygen consumption as compared to 
controls165.  The main finding from this study was a significant drop in diastolic blood 
pressure in a significant proportion of patients with exercise compared to controls165.  
This was not apparent in my study.  In a follow up study they demonstrated an 
improvement in exercise capacity with ERT166.  The drop in diastolic blood pressure 
seen in their original study was not replicated in the follow up study nor was there clear 
evidence for change in diastolic blood pressure response to exercise with ERT, 
particularly in patients included in both studies166.  Lobo et al. demonstrate similar 
exercise limitation with cardiopulmonary exercise testing, but their follow up cohort 
failed to show an improvement in exercise capacity with 1 year of ERT150.  These 
conflicting data question the utility of peak exercise oxygen consumption as a way of 
monitoring response to treatment. 
 
An interesting study by Spinelli et al. where patients with AFD underwent radionuclide 
angiography during rest and exercise along with resting echocardiography and cardiac 
MRI scanning and compared to controls167.  The study demonstrates that the majority 
of patients compared to controls had impaired exercise capacity. This impaired exercise 
capacity was associated with a failure to augment stroke volume with exercise and 
significant proportion having a reduction in stroke volume with exercise.  This study 
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suggests that the predominant mechanism for exercise intolerance is cardiac 
dysfunction as opposed to pulmonary, musculoskeletal or hypohidrosis. 
 
Coronary microvascular dysfunction 
Chapter 5 demonstrates that patients with AFD cardiomyopathy have coronary 
microvascular dysfunction when compared to normal controls and that this does not 
improve with enzyme replacement therapy, at least in the short-medium term.  These 
findings have been confirmed by other studies168, 169.  Up to 20% of patients experience 
anginal symptoms119 despite obstructive coronary artery disease being present in a 
minority of patients10.  Volumetric intravascular ultrasound analysis of the coronary 
tree in patients with AFD and chest pain showed that patients have diffuse involvement 
of their coronary arteries with plaques that are less echogenic170.  These findings are 
probably caused by Gb3 accumulation and disease-specific trophic influences rather 
than  accelerated atherosclerosis171.  Histologically, there is a diffuse storage 
arteriopathy affecting all parts of the arterial wall resulting in intimal thickening and 
vacuolation as well as medial hypertrophy76.  Additionally, there is significant 
calcification associated with the arteriopathy, as in classical atherosclerotic disease; 
however seems to be present in the media as opposed to the intima170.  Chimenti et al. 
have suggested that luminal narrowing of intramural arteries (due to GB3 deposition 
and hypertrophy in smooth muscle cells and endothelium) correlates with coronary 
flow and histological myocardial fibrosis172; suggesting that small vessel disease 
contributes to angina symptoms, myocardial fibrosis and potentially progressive heart 
failure in AFD cardiomyopathy172.  
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Extracellular matrix turnover 
Chapter 6 demonstrates that patients with AFD have abnormal extracellular matrix 
(ECM) turnover; the relation between MMP-9 levels and disease severity, as measured 
with the Mainz severity score index (MSSI), suggests that altered ECM remodelling is 
central to the pathogenesis of AFD related complications.  My study demonstrates that 
circulating MMP-9 is elevated in patients with AFD.  In patients with hypertrophic 
cardiomyopathy (HCM) caused by sarcomeric gene mutations, circulating MMP-2 levels 
and not MMP-9 levels are positively associated with left ventricular end systolic 
diameter, left atrial dimension and left ventricular systolic function173.  The same study 
also suggests that MMP-2 in HCM was associated with worse symptoms, higher 
circulating B type natriuretic peptide (BNP), and worse prognosis173.   
 
A recent study of N-terminal proBNP (NT-proBNP) in patients with AFD demonstrated 
that concentrations are increased in patients with AFD and correlate with non-invasive 
markers of diastolic dysfunction174. Increased NT-proBNP levels were present in 
patients without echocardiographic evidence of LV hypertrophy174. These ﬁndings 
suggest that measurement of NT-proBNP levels might assist in decisions on the timing 
of ERT174.  
 
Cardiac magnetic resonance (CMR) imaging studies suggest that 50% of males and 
females with AFD have late gadolinium enhancement in posterior LV wall segments63, 
175.  This late enhancement seen in AFD cardiomyopathy correlate with myocardial 
collagen deposition when comparing histologically with pre-mortem CMR scans (Figure 
1.5)158.  Importantly this macroscopic change in the extracellular matrix is associated 
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with a lack of regression of left ventricular hypertrophy or improvement in segmental 
myocardial function with ERT162, 176.    
 
Although a deficiency in A-Gal activity results in GB3 accumulation in numerous cell 
types, it is clear that this is only the start of a cascade of cellular signalling activation 
that lead to hypertrophy, apoptosis, necrosis and fibrosis.  The mechanisms underlying 
this cascade remain largely unknown.  Recently it has been suggested that a circulating 
growth promoting factor perhaps lyso-Gb3, may have a causative role in the 
development of LVH in the hearts of patients with AFD171, 177.  Another mechanism 
suggested for these cardiac changes was reported by Shen et al. They reported that 
excess intracellular GB3 induces oxidative stress and up regulation and expression of 
cellular adhesion molecules in vascular endothelial cells of patients, resulting in 
dysfunction of the coronary microvascular bed178.  It has also been reported that GB3 
accumulation alters mitochondrial energy metabolism.  Alterations in mitochondrial 
metabolism in the LV wall of patients with sarcomeric HCM can be replicated in skin 
ﬁbroblasts from patients with AFD disease, suggesting that GB3 deposits may cause 
disturbances in respiratory-chain activity, leading to reduced levels of creatinine 
phosphate, ADP, and ATP 179-181. 
 
Screening for AFD in defined populations 
I discussed new born screening for AFD in the introduction.  These specific studies have 
identified a higher than expected incidence of AFD.  These reported incidences are 
likely to still be an underestimation of the true incidence due to a failure to detect 
females and misdiagnosed cases.  New born screening for several other conditions 
124 
 
already exists and the addition of AFD to this would not pose a technical challenge.  
However, children lost to follow up, false positive rates, missed female cases and the 
lack of prospective longitudinal data to demonstrate the efficacy of this strategy28-30, 32-
34 result in an ethical dilemma of whether there should be wide spread use of this 
strategy.     
 
An alternative strategy is to target high risk populations and establish the prevalence 
of AFD in these populations (case finding studies) and then to screen the family of the 
identified individuals. These populations include patients on dialysis, with unexplained 
LVH and patients with cryptogenic stroke.  A systematic review of the literature by 
Linthorst et al in 2014 identified 20 studies (10 of which looked at males and females) 
that looked at screening of high risk populations.  The screening method was the 
identification of individual cases using A-Gal activity and then confirmatory genetic 
testing.  The overall prevalence for AFD in men on dialysis was 0.33% (95% CI 0.20% to 
0.47%) and 0.10% (95% CI 0% to 0.19%) in females.  The prevalence of AFD in males 
with renal transplants was 0.33% (95% CI 0.07% to 0.69%) and 0% in females.  
Methodological differences in the selection of the study population and screening 
techniques in the studies looking at patients with unexplained LVH hampered the 
calculation of the overall prevalence which ranged from 0.9% to 3.9% in men and 1.1% 
to 11.8% in women.  In premature strokes (n=2 studies), overall AFD prevalence was 
4.2% (95% CI 2.4% to 6.0%) in men and 2.1% (95% CI 0.5% to 3.7%) in women182.  
Interestingly, most of the studies looking at screening females for AFD used A-Gal 
activity, even though it is known that this method fails to diagnose up to a third of 
patients and hence the prevalence in females is likely to be an under estimate182. 
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Disease targeted therapies in AFD  
Since I completed the work in thesis, the impact of ERT has been evaluated in several 
observational studies. Several have demonstrated progression of cardiac disease 
(especially in those with established cardiac involvement) despite ERT76, 155, 183.  In the 
latest review from the Cochrane database of ERT, it concluded that ‘there is no robust 
evidence for ERT in AFD’184.  This may be in part to potential problems with the poor 
uptake of enzyme in cardiac and renal cells but is almost certainly also affected by the 
relatively late stage of disease at which ERT is commenced185, 186.   However, while 
robust evidence showing that ERT prevents hard endpoints is still lacking, treatment is 
not futile as symptoms such as neuropathic pain, hypohidrosis/anhidrosis improve and 
there is a reduction in the rate of progression of renal disease all resulting in an 
improved quality of life72, 73, 75, 155, 187-190.   
 
The two available ERT agents are produced in different ways as described in the 
introduction and infused at different doses.  Agalsidase alfa is infused at 0.2 mg/kg 
biweekly and agalsidase beta is infused at 1.0 mg/kg biweekly.  There are limited data 
available for head to head efficacy comparison. Vedder et al showed no effect when 
both products were dosed at 0.2 mg/kg biweekly191, however Beer et al, Imbriaco et al 
and Weidemann et al reported that left ventricular mass and measures of myocardial 
function were improved with agalsidase beta (1.0mg/kg biweekly) treatment74, 162, 176, 
192. Hughes et al and Baehner et al reported improved left ventricular mass in patients 
treated with agalsidase alfa193, 194.   
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A recent systematic review (including 31 studies) of the efficacy of ERT based on the 
stage of disease progression demonstrates that patients with a GFR>60 ml/min/1.73 
m2, the decline of renal function was similar for treated and untreated patients 
(historical controls), however males with a GFR<60 ml/min/1.73 m2 had a slower rate 
of decline in renal function, possibly attributable to anti- proteinuric therapy. 
Regardless of baseline LVH, LV mass remained stable or increased, albeit at a slower 
rate compared to historical controls when treated with ERT.  In females with LVH, LV 
mass decreased and in those without LVH, LV mass remained stable on ERT compared 
to historical controls.  There was no evidence to support the use of ERT to treat white 
matter lesions in AFD in this systematic review195.  This study highlights the difficulties 
in assessing the effectiveness of ERT in this chronic disease, there appears to be a 
differential effect of ERT in different organ systems as well as differing effects at 
different disease stages.  The true long term efficacy of ERT in this chronic disease 
remains uncertain. 
 
Small molecule ‘chaperone therapy’ either alone or in combination with ERT may also 
offer hope to patients with this disease196.  These molecules are inhibitors of the 
enzyme and can increase the catalytic activity of mutated forms of the enzyme, 
however, approximately 45% of patients have nonsense mutations in the A-Gal gene 
resulting in very low levels of the enzyme.  Future techniques to identify patients 
suitable for this therapy will assist in deciding who will benefit from this form of 
therapy197. 
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Several other therapies are under investigation. Substrate reduction therapy is 
accomplished by blocking specific enzymatic steps in the biosynthesis of the 
accumulating substance.  This form of therapy has been shown to help some patients 
with Gaucher Disease and has seen interest in the AFD community198.  The effect of an 
inhibitor of glucocerebroside biosynthesis was examined in Fabry knockout mice.  
There was a 50% reduction in Gb3 in kidneys, liver and heart following 8 weeks of intra-
peritoneal therapy with the inhibitor199.  The precise mechanism of Gb3 clearance is 
unclear, but deserves further investigation. 
 
The availability of the A-Gal knockout mice has made it possible to carry out critical 
experiments in regards to eventual gene therapy in patients with AFD200.  A single 
injection with a recombinant adeno-associated viral vector containing modified chicken 
α-actin promoter resulted in normalisation of Gb3 levels in the liver and spleen, with 
an 85% reduction in the heart and 66% reduction in the lungs at 6 months.  The kidney 
demonstrated an 82% reduction at 2 months, but had returned to 60% of the pre-
treatment levels at 6 months201, 202.  These are promising results that need further 
investigation, however gene therapy in this and many other metabolic conditions have 
been delayed due to the occurrence of insertional mutagenesis causing leukaemia in 
human recipients203.  There is hope that these oncogenic hazards will be eliminated by 
using self-inactivating lentival vectors in stem cell derived erythroid cells204. 
 
Limitations of this thesis 
Work subsequent to mine has demonstrated that there are techniques to identify AFD 
related cardiac disease early using advanced echocardiographic techniques such as 
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tissue Doppler and strain rate imaging74, 155, 162.  These were not in wide usage at the 
time of my studies and although FS was seen to decline in patients with advanced AFD, 
this is likely a reflection of progressive replacement fibrosis that occurs with disease 
progression76.  Additional imaging modalities such as cardiac MRI scanning, which has 
now been established as a method of differentiating underlying aetiologies of 
unexplained LVH would have added to this body of work158.  Additionally, subsequent 
work has suggested that other biomarkers such as brain naturetic peptide may be 
useful in identifying patients with early cardiac involvement with AFD cardiomyopathy 
and exploring this and other biomarkers would have added to this body of work174.  
 
Conclusions 
Together the chapters in my thesis demonstrate that progression of AFD 
cardiomyopathy is associated with cardiac systolic dysfunction and progressive 
arrhythmic disturbance.  These changes are associated with exercise limitation.  The 
underlying mechanisms are not clear, but it seems likely that coronary microvascular 
dysfunction and changes in the extracellular matrix play a role in the pathogenesis.  
There is a suggestion that early initiation of ERT, prior to cardiac fibrosis, may prevent 
progression of AFD cardiomyopathy, this however remains to be proven. 
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